{"id": "e8073f2c-91a8-40fb-bebb-639adcaba238", "page": 1, "type": "paragraph", "text": "HIGHLIGHTS OF PRESCRIBING INFORMATION"}
{"id": "9f9cb108-9487-4e1c-9535-4986a645254b", "page": 1, "type": "paragraph", "text": "These highlights do not include all the information needed to use Flublok\u00ae safely"}
{"id": "6eb4b5eb-f9ac-4efe-af6f-c256238a64f7", "page": 1, "type": "paragraph", "text": "and effectively. See full prescribing information for Flublok."}
{"id": "64eb6099-3d2f-47dd-a2e4-c45ba4681e46", "page": 1, "type": "paragraph", "text": "Flublok (In\ufb02uenza Vaccine)"}
{"id": "14e9a73d-82d3-4f65-b528-9971c66e3b18", "page": 1, "type": "paragraph", "text": "Injection for Intramuscular Use 2024-2025 Formula"}
{"id": "e7c48a8f-bc40-446e-892f-d8bfac0df0e7", "page": 1, "type": "paragraph", "text": "Initial U.S. Approval: 2013"}
{"id": "28fdd76c-dddc-46dd-8c59-560e846a0a6a", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "265065ff-5b3d-4d96-9366-13a773bf90ce", "page": 1, "type": "paragraph", "text": "INDICATIONS AND USAGE"}
{"id": "d6d72638-f261-40ba-8808-f0842bfa7f19", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "a08bb079-955d-4394-ac9e-2b75e207d760", "page": 1, "type": "paragraph", "text": "Flublok is a vaccine indicated for active immunization for the prevention of disease"}
{"id": "17389bf3-0fd8-4583-87ce-81aa3843e249", "page": 1, "type": "paragraph", "text": "caused by in\ufb02uenza A virus subtypes and in\ufb02uenza type B virus contained in the"}
{"id": "cf42edf9-2ba2-4d40-aad7-5e29abd6ecf9", "page": 1, "type": "paragraph", "text": "vaccine. Flublok is approved for use in persons 18 years of age and older. (1)"}
{"id": "2531c0b0-2e5f-4bb3-9f3a-83b96e1081d6", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "e39f5d51-caa5-48ed-8ec7-2f15eda2dea5", "page": 1, "type": "paragraph", "text": "DOSAGE AND ADMINISTRATION"}
{"id": "9dcc8d3b-c73c-440f-9470-8f879246a489", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "9f764b98-affe-436d-8e6c-3faa14e7ee41", "page": 1, "type": "paragraph", "text": "For intramuscular use (0.5 mL). (2)"}
{"id": "3df20ac5-b787-4446-a4c3-2256c8ae1a40", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "d5a1d91f-30e3-4a9c-986a-161c159f9577", "page": 1, "type": "paragraph", "text": "DOSAGE FORMS AND STRENGTHS"}
{"id": "6febe943-5df9-49f5-9470-dfb519ad3d26", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "90fd366f-5ebd-4073-bec6-3373e8c9a487", "page": 1, "type": "paragraph", "text": "Flublok is an injection, a single dose is 0.5mL. (3)"}
{"id": "f6d1901f-fd14-4e53-925e-c23c9c4a0164", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "9ce0b873-43b3-418e-b0c1-9f881d1c95e2", "page": 1, "type": "paragraph", "text": "CONTRAINDICATIONS"}
{"id": "68bdb094-324d-4a84-af91-6804aefcc89d", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "4292b579-f38d-4ae6-b44d-87a7fe61e48f", "page": 1, "type": "paragraph", "text": "\u2022 Do not administer Flublok to anyone with a history of severe allergic reactions"}
{"id": "87b70a2e-b758-43a8-9575-efb70e1e795d", "page": 1, "type": "paragraph", "text": "(e.g., anaphylaxis) to any component of the vaccine. (4, 6.2, 11)"}
{"id": "a22620d9-cf15-4081-830b-4469a2496e73", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "17aaf6a6-f24f-4435-8984-ec12a4fbaea6", "page": 1, "type": "paragraph", "text": "WARNINGS AND PRECAUTIONS"}
{"id": "87488eb0-d20d-4685-8b5b-b87d81b56ff9", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "2b2dae1b-e011-4cf7-b13e-75656572770b", "page": 1, "type": "paragraph", "text": "\u2022 Appropriate medical treatment must be immediately available to manage potential"}
{"id": "6d3b8743-0ff3-4549-a960-9a21c2f8916d", "page": 1, "type": "paragraph", "text": "anaphylactic reactions following administration of Flublok. (5.1)"}
{"id": "7ed88b33-7077-4490-a8fe-d4edb5f6996e", "page": 1, "type": "paragraph", "text": "\u2022 If Guillain-Barr\u00e9 syndrome has occurred within 6 weeks of receipt of a prior"}
{"id": "ac6d19d0-c908-4f74-bac5-dddbd1a9482c", "page": 1, "type": "paragraph", "text": "in\ufb02uenza vaccine, the decision to give Flublok should be based on careful"}
{"id": "6d27c1f8-67fe-40a5-8920-758ea5287d12", "page": 1, "type": "paragraph", "text": "consideration of potential bene\ufb01ts and risks. (5.2)"}
{"id": "39593106-d719-4a85-8a1b-7e5ce67b3fe7", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "7970317d-e349-433c-87e3-275cea65a0be", "page": 1, "type": "paragraph", "text": "ADVERSE REACTIONS"}
{"id": "63f18860-e17d-41c6-a3fc-fa6efbc6721f", "page": 1, "type": "paragraph", "text": "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"}
{"id": "c67322c3-8779-4a00-91f8-6e2c3e310284", "page": 1, "type": "paragraph", "text": "\u2022 In adults 18 through 49 years of age, the most common (\u226510%) injection-site"}
{"id": "83f2b960-106c-46a8-92ed-e106dccc09ef", "page": 1, "type": "paragraph", "text": "adverse reaction was pain (37%); the most common (\u226510%) solicited systemic"}
{"id": "5d97f93f-5914-427f-ba37-b0eef08d788a", "page": 1, "type": "paragraph", "text": "adverse reactions were headache (15%), fatigue (15%) and muscle pain (11%)."}
{"id": "63905271-8347-4ad1-a052-903176020591", "page": 1, "type": "paragraph", "text": "(6.1)"}
{"id": "51824420-37be-4aaa-a748-b1e3f06e4f51", "page": 1, "type": "paragraph", "text": "\u2022 In adults 50 through 64 years of age, the most common (\u226510%) injection site"}
{"id": "3016da45-6876-4710-9492-1098a4011754", "page": 1, "type": "paragraph", "text": "adverse reaction was pain (32%); the most common (\u226510%) solicited systemic"}
{"id": "e2895817-c3bd-4ea6-8c92-f0a57a9b6c92", "page": 1, "type": "paragraph", "text": "adverse reactions were headache (17%), fatigue (13%), and muscle pain (11%)."}
{"id": "ac60d2b1-05c0-461d-9caa-94227b913bfa", "page": 1, "type": "paragraph", "text": "(6.1)"}
{"id": "4c676f34-2a3e-425b-b465-2b5602833430", "page": 1, "type": "paragraph", "text": "\u2022 In adults 65 years of age and older, the most common (\u226510%) injection site"}
{"id": "0ca88836-b06d-4267-ae94-46b63cea8336", "page": 1, "type": "paragraph", "text": "adverse reaction was pain (19%); the most common (\u226510%) solicited systemic"}
{"id": "921e4a42-b3de-4d3f-84ee-488a698b9281", "page": 1, "type": "paragraph", "text": "adverse reactions were fatigue (13%) and headache (10%). (6.1)"}
{"id": "7a9da180-4d8b-4e48-b8c3-55ba902cf88d", "page": 1, "type": "paragraph", "text": "To report SUSPECTED ADVERSE REACTIONS, contact Sano\ufb01Pasteur Inc., at"}
{"id": "56fca929-115b-43e0-b2af-d931d9198932", "page": 1, "type": "paragraph", "text": "(1-800-822-2463"}
{"id": "3267d1eb-8364-4a97-812b-9b75ae90cf50", "page": 1, "type": "paragraph", "text": "(1-800-Vaccine)"}
{"id": "e289b829-1bd0-4994-8471-fe24f66acf93", "page": 1, "type": "paragraph", "text": "or"}
{"id": "66daa2e0-78bb-4bff-8323-4c86c1d1f7f2", "page": 1, "type": "paragraph", "text": "VAERS"}
{"id": "e1f9a0ea-8e7e-40e6-a9c7-4fc3cb7ab085", "page": 1, "type": "paragraph", "text": "at"}
{"id": "8c99bd0a-fc5a-41fe-9a42-f4a866858f9c", "page": 1, "type": "paragraph", "text": "1-800-822-7967"}
{"id": "0df71b72-e327-4295-80fd-8a8969ce3a86", "page": 1, "type": "paragraph", "text": "or"}
{"id": "5459a1d0-1518-48c7-bf0f-fad80da7991f", "page": 1, "type": "paragraph", "text": "www.vaers.hhs.gov."}
{"id": "2ec993f3-ac62-4604-bf12-15a9ffff6603", "page": 1, "type": "paragraph", "text": "See 17 for PATIENT COUNSELING INFORMATION"}
{"id": "bb719a24-5488-4e48-9634-38be10353043", "page": 1, "type": "paragraph", "text": "Revised: 07/2024"}
{"id": "820d954b-a0a2-48b6-99bc-e8741525ea46", "page": 1, "type": "paragraph", "text": "FULL PRESCRIBING INFORMATION: CONTENTS*"}
{"id": "abb0767b-442b-4e31-9d50-9a42c727a9db", "page": 1, "type": "paragraph", "text": "1"}
{"id": "92ef3a62-3832-434d-92d2-3f1afa2396a8", "page": 1, "type": "paragraph", "text": "INDICATIONS AND USAGE"}
{"id": "bcc297b9-2aaf-4f22-a0f5-b3ea8f624e88", "page": 1, "type": "paragraph", "text": "2"}
{"id": "2d38db3b-194c-47a2-8569-f1dc87c26442", "page": 1, "type": "paragraph", "text": "DOSAGE AND ADMINISTRATION"}
{"id": "9858ecf5-e70a-41ca-97e5-58e38f1c0375", "page": 1, "type": "paragraph", "text": "2.1"}
{"id": "3f0fc0d6-35df-4559-97ea-3d0462ee3b69", "page": 1, "type": "paragraph", "text": "Dosage"}
{"id": "d9821afc-f952-445b-ad26-8774e94bc029", "page": 1, "type": "paragraph", "text": "2.2"}
{"id": "2351b3d3-eac6-4809-a188-946319aedd42", "page": 1, "type": "paragraph", "text": "Administration"}
{"id": "83c24a4b-6142-44df-80fc-452a3607d6fd", "page": 1, "type": "paragraph", "text": "3"}
{"id": "409b9787-ae53-4762-81a6-b7a76ade9399", "page": 1, "type": "paragraph", "text": "DOSAGE FORMS AND STRENGTHS"}
{"id": "89d23ea4-7ef8-49e8-9e6a-3eca7997b358", "page": 1, "type": "paragraph", "text": "4"}
{"id": "27ffeb0e-890f-40ba-9443-f2daea146eee", "page": 1, "type": "paragraph", "text": "CONTRAINDICATIONS"}
{"id": "17feb0b5-af74-4f53-93d9-c5cee86d882c", "page": 1, "type": "paragraph", "text": "5"}
{"id": "c3692797-67de-447a-a851-3b21570e79e1", "page": 1, "type": "paragraph", "text": "WARNINGS AND PRECAUTIONS"}
{"id": "18e2e4a1-c2a8-42c2-b6c0-178411f449cd", "page": 1, "type": "paragraph", "text": "5.1"}
{"id": "c738c432-b25f-49e9-94cf-116c7947f244", "page": 1, "type": "paragraph", "text": "Managing Allergic Reactions"}
{"id": "bedbf13d-a868-4988-b53e-e0957e7f6a60", "page": 1, "type": "paragraph", "text": "5.2"}
{"id": "a61913de-41a7-42dc-86a6-c56a3eaf71b8", "page": 1, "type": "paragraph", "text": "Guillain-Barr\u00e9 Syndrome"}
{"id": "c56be402-59d7-4792-b1ad-18afca3a1fb0", "page": 1, "type": "paragraph", "text": "5.3"}
{"id": "cadd17e6-1842-4f76-b376-9a42246faff9", "page": 1, "type": "paragraph", "text": "Altered Immunocompetence"}
{"id": "cd5b15f8-6bfa-4ee4-94a6-ffceea3d4609", "page": 1, "type": "paragraph", "text": "5.4"}
{"id": "20ed1264-5316-4420-a035-f00f31fa7666", "page": 1, "type": "paragraph", "text": "Limitations of Vaccine Effectiveness"}
{"id": "9dc6cd76-ac5d-4931-8630-d54bd70fdeec", "page": 1, "type": "paragraph", "text": "5.5"}
{"id": "0f2ee0d8-a074-49f7-a5a7-4a2d3f968d36", "page": 1, "type": "paragraph", "text": "Syncope"}
{"id": "7af53074-5bd5-47a4-9f18-49348dddd561", "page": 1, "type": "paragraph", "text": "6"}
{"id": "2422f5de-bf93-47a6-b0d4-c7228da224ed", "page": 1, "type": "paragraph", "text": "ADVERSE REACTIONS"}
{"id": "a1939a43-0375-4ab5-aa99-7a9199111362", "page": 1, "type": "paragraph", "text": "6.1"}
{"id": "825fd1c0-5929-43dd-8b28-b75ca5230b58", "page": 1, "type": "paragraph", "text": "Clinical Trials Experience"}
{"id": "0277fb15-0e33-4b86-b4c0-f5b82e599da2", "page": 1, "type": "paragraph", "text": "6.2"}
{"id": "fd1d18a1-959a-4a27-960c-cced5d036ea0", "page": 1, "type": "paragraph", "text": "Postmarketing Experience"}
{"id": "b0b6901c-1381-44c2-9f57-3f620c0b4ab4", "page": 1, "type": "paragraph", "text": "8"}
{"id": "46a02796-0bed-45b5-b88f-854e4948019c", "page": 1, "type": "paragraph", "text": "USE IN SPECIFIC POPULATIONS"}
{"id": "679f83bc-9fc5-408b-aa84-e96f0db25a9a", "page": 1, "type": "paragraph", "text": "8.1"}
{"id": "da91ab95-9278-4347-b88e-e429ed523efb", "page": 1, "type": "paragraph", "text": "Pregnancy"}
{"id": "20f7c720-8588-4687-aa68-57e45f1db067", "page": 1, "type": "paragraph", "text": "8.2"}
{"id": "dbba9935-f4ee-4c1d-9e54-e76d1519b7d0", "page": 1, "type": "paragraph", "text": "Lactation"}
{"id": "4ab2bf65-ddc0-4478-8d99-bc9c92f3ffac", "page": 1, "type": "paragraph", "text": "8.4"}
{"id": "8347c294-f521-4a39-8e22-89464538c334", "page": 1, "type": "paragraph", "text": "Pediatric Use"}
{"id": "ceb7453c-64b7-4122-85dc-888348377a96", "page": 1, "type": "paragraph", "text": "8.5"}
{"id": "63ead07b-cd7f-4d1d-8b74-38d150291d20", "page": 1, "type": "paragraph", "text": "Geriatric Use"}
{"id": "98b81b9b-de0d-4a76-9b75-116fde381f83", "page": 1, "type": "paragraph", "text": "11"}
{"id": "cdd44561-80bb-4fa5-8929-d7f5e92b07e9", "page": 1, "type": "paragraph", "text": "DESCRIPTION"}
{"id": "9ec5a8de-1b2c-4146-a847-8b4a0632e7f3", "page": 1, "type": "paragraph", "text": "12"}
{"id": "ad67925e-3bdd-402c-b170-044c1f60356b", "page": 1, "type": "paragraph", "text": "CLINICAL PHARMACOLOGY"}
{"id": "14d84963-96c2-491b-9771-e0e61d42cea2", "page": 1, "type": "paragraph", "text": "12.1"}
{"id": "daf3e81f-c851-48bd-9681-d271d5ecaccd", "page": 1, "type": "paragraph", "text": "Mechanism of Action"}
{"id": "acc0acad-6950-4d91-b23e-35a9aea8923f", "page": 1, "type": "paragraph", "text": "13"}
{"id": "1f5f5e9b-cd60-46ff-911e-20e4008069cf", "page": 1, "type": "paragraph", "text": "NONCLINICAL TOXICOLOGY"}
{"id": "cf5319bd-184c-4bc1-8974-37d3685a54de", "page": 1, "type": "paragraph", "text": "13.1"}
{"id": "8d04c3fc-18d6-4f7f-8bb1-24bbd5092cf0", "page": 1, "type": "paragraph", "text": "Carcinogenesis, Mutagenesis, Impairment of Fertility"}
{"id": "a8311932-c8d8-4654-9ab9-e4b3a0914e86", "page": 1, "type": "paragraph", "text": "14"}
{"id": "4bbf9ea2-c3cd-4d2f-a048-db5f7d668df1", "page": 1, "type": "paragraph", "text": "CLINICAL STUDIES"}
{"id": "af19b707-3bd2-4a68-b5c9-56faccdae6e5", "page": 1, "type": "paragraph", "text": "14.1"}
{"id": "10a53c90-b8b6-4433-91d2-b7484dade08a", "page": 1, "type": "paragraph", "text": "Efficacy Against Laboratory-Con\ufb01rmed In\ufb02uenza"}
{"id": "d13c9063-8ff6-41a0-bf3d-3c5cff40aef6", "page": 1, "type": "paragraph", "text": "15"}
{"id": "f709c681-d8c0-4341-8349-bae091962fdd", "page": 1, "type": "paragraph", "text": "REFERENCES"}
{"id": "c649612e-b3da-4bcf-ba81-d1af86dfb57a", "page": 1, "type": "paragraph", "text": "16"}
{"id": "9135f7f2-83c4-4d28-92b4-c3c7d09ca6da", "page": 1, "type": "paragraph", "text": "HOW SUPPLIED/STORAGE AND HANDLING"}
{"id": "e0a4b28c-2aee-4b6d-9de4-4193b401891f", "page": 1, "type": "paragraph", "text": "16.1"}
{"id": "11188a01-934c-4308-8dd7-9c66f0fdad50", "page": 1, "type": "paragraph", "text": "How Supplied"}
{"id": "a852f3c9-f2ab-4dd5-ad08-adb64a39feb8", "page": 1, "type": "paragraph", "text": "16.2"}
{"id": "cb86e1dd-e0bb-487e-8959-e751862c1f9a", "page": 1, "type": "paragraph", "text": "Storage and Handling"}
{"id": "4fc5bcc7-ea5b-4003-91aa-0fcf5d9e7955", "page": 1, "type": "paragraph", "text": "17"}
{"id": "02dca3b8-2ce5-4d6f-9e8c-911a38593016", "page": 1, "type": "paragraph", "text": "PATIENT COUNSELING INFORMATION"}
{"id": "49f1d93f-790f-461e-b066-8446cbf2d3ce", "page": 1, "type": "paragraph", "text": "*Sections or subsections omitted from the full prescribing information are not"}
{"id": "cbc01337-5f23-4186-8c9b-c36ba2fa86cd", "page": 1, "type": "paragraph", "text": "listed"}
{"id": "3c76ce33-cb02-41d3-9cd9-0412f4cc547d", "page": 1, "type": "paragraph", "text": "FULL PRESCRIBING INFORMATION"}
{"id": "f83ba8ea-1b62-4543-8a99-83ec73ee8908", "page": 1, "type": "paragraph", "text": "1"}
{"id": "2b92d261-51f2-47e5-b435-899fb26f2a7d", "page": 1, "type": "paragraph", "text": "INDICATIONS AND USAGE"}
{"id": "0c331eda-44bb-4d45-8030-295ec6e3a2e3", "page": 1, "type": "paragraph", "text": "Flublok is a vaccine indicated for active immunization for the prevention of disease caused"}
{"id": "500337f4-566c-41e3-870e-9d2c024eebf9", "page": 1, "type": "paragraph", "text": "by in\ufb02uenza A virus subtypes and in\ufb02uenza type B virus contained in the vaccine. Flublok"}
{"id": "c974d175-9160-4c7c-8011-aab0b0f8f85d", "page": 1, "type": "paragraph", "text": "is approved for use in persons 18 years of age and older."}
{"id": "7fda015f-56c2-4386-a318-5a04489e166e", "page": 1, "type": "paragraph", "text": "2"}
{"id": "33a82bde-d388-4201-887e-d489e0d8f2f0", "page": 1, "type": "paragraph", "text": "DOSAGE AND ADMINISTRATION"}
{"id": "7ab3ae93-954f-4c6b-95a2-25d40aa658d1", "page": 1, "type": "paragraph", "text": "For intramuscular use."}
{"id": "3b0d1c3d-3912-4436-80bc-0acc41981196", "page": 1, "type": "paragraph", "text": "2.1"}
{"id": "7042c278-7348-458b-b6f6-0c8cec6a1190", "page": 1, "type": "paragraph", "text": "Dosage"}
{"id": "63d34211-3f15-4e30-9df2-7be8b0c6c582", "page": 1, "type": "paragraph", "text": "Administer Flublok as a single 0.5 mL dose."}
{"id": "73863269-4491-46c8-9608-1185cef3d984", "page": 1, "type": "paragraph", "text": "2.2"}
{"id": "3e20aeaf-dfad-4009-8060-15d71ed8812c", "page": 1, "type": "paragraph", "text": "Administration"}
{"id": "a779f15f-d11d-45bb-9c39-91209559cdfc", "page": 1, "type": "paragraph", "text": "Parenteral drug products should be inspected visually for particulate matter and discol-"}
{"id": "420074f2-7ea8-4dad-b8a1-3d5d43373c62", "page": 1, "type": "paragraph", "text": "oration prior to administration whenever solution and container permit. If either of these"}
{"id": "ac32a2ba-8210-4b25-b46e-2d32074f8179", "page": 1, "type": "paragraph", "text": "conditions exists, the vaccine should not be administered."}
{"id": "1c328384-0668-49f2-a434-625be6c0e530", "page": 1, "type": "paragraph", "text": "Gently invert the pre\ufb01lled syringe prior to affixing a sterile needle."}
{"id": "ff57a3a6-3735-4daa-bb67-0637012d9f0e", "page": 1, "type": "paragraph", "text": "Administer the dose intramuscularly."}
{"id": "24fbaa52-7208-4f7e-89a4-bc0dfe285b43", "page": 1, "type": "paragraph", "text": "3"}
{"id": "f1c2f978-3d0f-4276-8712-137271b6c2f0", "page": 1, "type": "paragraph", "text": "DOSAGE FORMS AND STRENGTHS"}
{"id": "6b5ad981-ab88-4002-86de-c078b9152d45", "page": 1, "type": "paragraph", "text": "Flublok is an injection. A single dose is 0.5 mL."}
{"id": "4b6a95ec-d51b-48aa-b93c-9bd86b5c35c4", "page": 1, "type": "paragraph", "text": "4"}
{"id": "cd5be0f7-4e03-44c5-a1fc-9be54d76c482", "page": 1, "type": "paragraph", "text": "CONTRAINDICATIONS"}
{"id": "cbe8bcc0-4902-404b-9a38-ebdc01045b1f", "page": 1, "type": "paragraph", "text": "Do not administer Flublok to anyone with a history of severe allergic reactions (e.g.,"}
{"id": "ec123602-9f1b-4038-b594-6695c9bba3ad", "page": 1, "type": "paragraph", "text": "anaphylaxis) to any component of the vaccine. [see Postmarketing Experience [6.2] and"}
{"id": "77f7fab7-9645-4c5a-80a1-5e2735b6eca2", "page": 1, "type": "paragraph", "text": "Description (11)]."}
{"id": "d303537e-322b-4f67-b8d1-22ce32e516b6", "page": 1, "type": "paragraph", "text": "5"}
{"id": "1f46f15b-4a4f-4f21-abb5-c72a2779bb72", "page": 1, "type": "paragraph", "text": "WARNINGS AND PRECAUTIONS"}
{"id": "05da9505-464a-42b7-b507-42fc88b94abd", "page": 1, "type": "paragraph", "text": "5.1"}
{"id": "2c727c35-1f6a-4134-ab51-9ae1759f755d", "page": 1, "type": "paragraph", "text": "Managing Allergic Reactions"}
{"id": "6d5e297d-d3dc-4686-ac4f-a091d87171ce", "page": 1, "type": "paragraph", "text": "Appropriate medical treatment must be immediately available to manage potential"}
{"id": "2062f582-b10c-459b-a1b8-077f8c79f7bd", "page": 1, "type": "paragraph", "text": "anaphylactic reactions following administration of Flublok."}
{"id": "674e9eb5-08f6-4749-b32d-ff15bab40aee", "page": 1, "type": "paragraph", "text": "5.2"}
{"id": "cadfaf22-0500-4fe1-b37a-caa5a114ce79", "page": 1, "type": "paragraph", "text": "Guillain-Barr\u00e9 Syndrome"}
{"id": "2d7eff37-e21d-4987-be3a-03db2b08b707", "page": 1, "type": "paragraph", "text": "If GBS has occurred within 6 weeks of receipt of a prior in\ufb02uenza vaccine, the decision"}
{"id": "551ca787-931e-4d1b-9620-30fc18a930f1", "page": 1, "type": "paragraph", "text": "to give Flublok should be based on careful consideration of the potential bene\ufb01ts and risks."}
{"id": "ac64fc98-a1b1-4814-bc3a-12c919e28c46", "page": 1, "type": "paragraph", "text": "The 1976 swine in\ufb02uenza vaccine was associated with an increased frequency of"}
{"id": "9bc23998-8eac-4ef1-8462-88798b7ff1b5", "page": 1, "type": "paragraph", "text": "Guillain-Barr\u00e9 Syndrome (GBS). Evidence for a causal relation of GBS with other in\ufb02uenza"}
{"id": "b723d1e1-e1c6-42d6-86fe-f8753e0d477f", "page": 1, "type": "paragraph", "text": "vaccines is inconclusive; if an excess risk exists, it is probably slightly more than one"}
{"id": "78a6a3a9-f712-435b-a9f0-92b9627560af", "page": 1, "type": "paragraph", "text": "additional case per 1 million persons vaccinated."}
{"id": "8c50b9a4-6459-4fd7-b6e9-ea4662396e78", "page": 1, "type": "paragraph", "text": "5.3"}
{"id": "ec3711b8-82e6-4713-8241-ebb3eb19e9ac", "page": 1, "type": "paragraph", "text": "Altered Immunocompetence"}
{"id": "fb62e174-2d43-4425-afd5-4396bd3db733", "page": 1, "type": "paragraph", "text": "If Flublok is administered to immunocompromised individuals, including persons receiving"}
{"id": "16212fee-d4a4-428e-9c5f-281c7a67c3ea", "page": 1, "type": "paragraph", "text": "immunosuppressive therapy, the immune response may be diminished."}
{"id": "ad203d8c-8611-46cb-91be-221444509dcd", "page": 1, "type": "paragraph", "text": "5.4"}
{"id": "42790a4a-5ffb-4607-bea0-06dd27cb495e", "page": 1, "type": "paragraph", "text": "Limitations of Vaccine Effectiveness"}
{"id": "98d5ca0b-b97b-4da5-980e-ba18e8336159", "page": 1, "type": "paragraph", "text": "Vaccination with Flublok may not protect all vaccine recipients."}
{"id": "450733db-9a3c-400c-bb0b-dce2e1d12f43", "page": 1, "type": "paragraph", "text": "5.5"}
{"id": "5b04be79-4e3e-4fdc-97c7-953e2dca6f04", "page": 1, "type": "paragraph", "text": "Syncope"}
{"id": "5643efd7-59d2-4419-aba9-bcd79b08b2cd", "page": 1, "type": "paragraph", "text": "Syncope (fainting) has been reported following vaccination with Flublok. Procedures"}
{"id": "bb5796d4-04f7-4721-bd2a-404dfc0423cc", "page": 1, "type": "paragraph", "text": "should be in place to avoid injury from fainting."}
{"id": "d499b6fe-2349-4f11-b7cd-dcde1697bff5", "page": 1, "type": "paragraph", "text": "6"}
{"id": "165bc1d3-5391-466c-a751-9c19b6044b1d", "page": 1, "type": "paragraph", "text": "ADVERSE REACTIONS"}
{"id": "cfb57ad7-115a-4440-aa29-c3f88ab9bdca", "page": 1, "type": "paragraph", "text": "In adults 18 through 49 years of age, the most common (\u226510%) injection-site adverse"}
{"id": "0c1b2353-d482-4dbf-9a65-dc8772d168f9", "page": 1, "type": "paragraph", "text": "reaction was pain (37%); the most common (\u226510%) solicited systemic adverse reactions"}
{"id": "c6737e23-8bb7-42d3-afe3-f525e1d5ee46", "page": 1, "type": "paragraph", "text": "were headache (15%), fatigue (15%) and muscle pain (11%). (6.1)"}
{"id": "3d1078d5-e4a0-4a07-9d18-949abd871205", "page": 1, "type": "paragraph", "text": "In adults 50 through 64 years of age, the most common (\u226510%) injection site adverse"}
{"id": "16579110-c579-4387-9ad2-25dc2f2392e1", "page": 1, "type": "paragraph", "text": "reaction was pain (32%); the most common (\u226510%) solicited systemic adverse reactions"}
{"id": "4017ada1-97c9-4142-ae3d-b44d4c2621dd", "page": 1, "type": "paragraph", "text": "were headache (17%), fatigue (13%), and muscle pain (11%). (6.1)"}
{"id": "ee030846-c5e0-4cd9-b09e-40779f88006f", "page": 1, "type": "paragraph", "text": "In adults 65 years of age and older, the most common (\u226510%) injection site adverse"}
{"id": "f364126f-a8f3-4b2e-98d0-fc7759bc8607", "page": 1, "type": "paragraph", "text": "reaction was pain (19%); the most common (\u226510%) solicited systemic adverse reactions"}
{"id": "d8c4b232-eb88-4013-acec-9d7c08f13be8", "page": 1, "type": "paragraph", "text": "were fatigue (13%) and headache (10%). (6.1)"}
{"id": "aac259d1-f1e4-4428-8c57-f6dfd023a3fa", "page": 1, "type": "paragraph", "text": "6.1"}
{"id": "25b279d2-d4e9-464f-9393-9b17c4142f4c", "page": 1, "type": "paragraph", "text": "Clinical Trials Experience"}
{"id": "4495b8b7-27a4-4f86-a10a-603b0bc7fcae", "page": 1, "type": "paragraph", "text": "Because clinical studies are conducted under widely varying conditions, adverse reaction"}
{"id": "c96bf47f-8c3c-4868-8350-c1818222e54c", "page": 1, "type": "paragraph", "text": "rates observed in the clinical studies of a vaccine cannot be directly compared to rates"}
{"id": "f2c89cc5-cb0d-4b6d-bc23-8e94ac72e46e", "page": 1, "type": "paragraph", "text": "in the clinical studies of another vaccine and may not re\ufb02ect the rates observed in clinical"}
{"id": "9ccdc202-b458-4978-91f4-2081f1245de2", "page": 1, "type": "paragraph", "text": "practice."}
{"id": "e7f416a5-2d98-4256-ae8f-ff09fe82afb3", "page": 1, "type": "paragraph", "text": "The safety experience with Flublok Quadrivalent is relevant to Flublok because both"}
{"id": "112e54fe-bc82-48e5-a0d6-9e75b9fc3985", "page": 1, "type": "paragraph", "text": "vaccines are manufactured using the same process and have overlapping compositions."}
{"id": "b7282153-c0cd-46e1-b63e-926f0392119c", "page": 1, "type": "paragraph", "text": "Flublok"}
{"id": "cdebfe6c-4cb3-4a58-b8e7-795b7dfec486", "page": 1, "type": "paragraph", "text": "Flublok has been administered to and safety data collected from 2497 adults 18 through"}
{"id": "5b3b6472-d2b7-4ecf-819b-0d7496c81607", "page": 1, "type": "paragraph", "text": "49 years of age, 972 adults 50 through 64 years of age, and 1078 adults aged 65 years"}
{"id": "fbb78ea6-ccfa-44b6-a411-84459e34a943", "page": 1, "type": "paragraph", "text": "and older enrolled in \ufb01ve randomized, placebo- or active-controlled clinical trials. Clinical"}
{"id": "8ab35005-6e3c-4a0a-8d55-ed693b903db8", "page": 1, "type": "paragraph", "text": "safety data for Flublok are presented from four clinical trials (Studies 1, 2, 3, and 4). Data"}
{"id": "fc6c9977-d41d-4625-a45a-f745dfe7dbee", "page": 1, "type": "paragraph", "text": "from a placebo-controlled trial in adults 18 through 49 years of age (Study 1) are"}
{"id": "3b992798-d0f3-4acd-8a0f-ccab6a5cda5c", "page": 1, "type": "paragraph", "text": "presented, followed by data pooled according to age group from Studies 2 and 4 (adults"}
{"id": "80f804f9-7e48-4852-951f-00dd4f82f420", "page": 1, "type": "paragraph", "text": "50 through 64 years of age) and Studies 3 and 4 (adults aged 65 years and older)."}
{"id": "946872dd-f47f-4eda-ab79-878d2721678b", "page": 1, "type": "paragraph", "text": "1"}
{"id": "214ea55a-0bd8-4c07-b43a-73a67d3b090e", "page": 2, "type": "paragraph", "text": "Reactogenicity data from a small Phase 2 trial (Study 5) in adults 18 through 49 years of"}
{"id": "528cdaee-9860-48e9-b2ba-cb256d37c0c6", "page": 2, "type": "paragraph", "text": "age, 153 of whom received Flublok 135mcg, are not presented. However, subjects from"}
{"id": "228e4623-ddbe-4402-9cdd-56c0b1261343", "page": 2, "type": "paragraph", "text": "Study 5 are included in the description of deaths and serious adverse events (SAEs). In"}
{"id": "06d29d37-4e4b-4337-991e-f72d5637b402", "page": 2, "type": "paragraph", "text": "all studies local (injection site) and systemic adverse reactions were solicited with the use"}
{"id": "f0b485ad-d766-4293-8d3d-d4be3b6a8124", "page": 2, "type": "paragraph", "text": "of a memory aid for 7 days following vaccination, and unsolicited adverse reactions were"}
{"id": "9c32b09c-806d-4c61-9d36-23dd80960384", "page": 2, "type": "paragraph", "text": "collected for 28-30 days post-vaccination. In Studies 1- 3 and 5, SAEs were collected for"}
{"id": "962f0dac-f445-4f53-8b57-f6901a7f5ffd", "page": 2, "type": "paragraph", "text": "6 months post-vaccination via clinic visit or telephone follow up on Day 28, telephone"}
{"id": "ae30d779-e582-4a5e-af20-8ef3bf2e61bd", "page": 2, "type": "paragraph", "text": "follow up on Day 180, or by spontaneous reporting. Study 4 collected SAEs through 30"}
{"id": "a6ce5c68-19c2-4106-9eac-442099347f78", "page": 2, "type": "paragraph", "text": "days following receipt of vaccine. Study 4 also actively solicited pre-speci\ufb01ed common"}
{"id": "82874c8b-d84f-4adf-9160-76a65b466213", "page": 2, "type": "paragraph", "text": "hypersensitivity-type reactions through 30 days following receipt of vaccine as a primary"}
{"id": "2eecf139-5a98-43ad-b3f2-6cf074a34967", "page": 2, "type": "paragraph", "text": "endpoint."}
{"id": "14915a04-787d-4199-aed1-58ffd1af0014", "page": 2, "type": "paragraph", "text": "Study 1 (NCT00539981) included 4648 subjects 18 through 49 years of age for safety"}
{"id": "a815e1c9-a0a7-42b6-b67f-0be31d4160ea", "page": 2, "type": "paragraph", "text": "analysis, randomized to receive Flublok (n=2344) or placebo (n=2304) (1) (see Clinical"}
{"id": "7ae632ef-1d2c-41a0-86ab-c56cb68653d1", "page": 2, "type": "paragraph", "text": "Studies [14.1])."}
{"id": "851af281-9f25-4c30-9552-e0d0f7248288", "page": 2, "type": "paragraph", "text": "Study 2 (NCT00539864) included 602 subjects 50 through 64 years of age for safety"}
{"id": "064c1805-6f36-44ec-a461-fd29f21f8fd8", "page": 2, "type": "paragraph", "text": "analysis, randomized to receive Flublok (n=300) or another U.S.-licensed trivalent"}
{"id": "2020f69e-5415-4c20-b6c3-0fc313ca39f5", "page": 2, "type": "paragraph", "text": "in\ufb02uenza vaccine (Fluzone, manufactured by Sano\ufb01Pasteur, Inc.) as an active control"}
{"id": "fcfde228-4fc4-4329-b53d-c4770ca28f44", "page": 2, "type": "paragraph", "text": "(n=302) (2)."}
{"id": "62c5d5c8-62eb-4b8f-949e-4f1fa059fb9e", "page": 2, "type": "paragraph", "text": "Study 3 (NCT00395174) included 869 subjects aged 65 years and older for safety"}
{"id": "eece18a1-4599-4e87-bd45-8c32f5f47419", "page": 2, "type": "paragraph", "text": "analysis, randomized to receive Flublok (n=436) or another U.S.-licensed trivalent"}
{"id": "b7588a4b-bde8-472e-b1df-5067ff4e3986", "page": 2, "type": "paragraph", "text": "in\ufb02uenza vaccine (Fluzone) as an active control (n=433) (3)."}
{"id": "7ba3e0d7-0c43-415c-ba8b-e0a28cc7e523", "page": 2, "type": "paragraph", "text": "Study 4 (NCT01825200) included 2627 subjects aged 50 years and older for safety"}
{"id": "f2fc3139-a9ad-4153-898e-68bdd4929f91", "page": 2, "type": "paragraph", "text": "analysis, randomized to receive Flublok (n=1314) or another U.S.-licensed trivalent"}
{"id": "8b131fe5-96a6-4f24-9b34-f84f6515d9c9", "page": 2, "type": "paragraph", "text": "in\ufb02uenza vaccine (A\ufb02uria, manufactured by bioCSL Pty Ltd.) as an active control (n=1313)."}
{"id": "afdff7da-745b-4eca-9525-458a8f0b7a39", "page": 2, "type": "paragraph", "text": "Among subjects 50 through 64 years of age, 672 received Flublok and 665 received"}
{"id": "9abd930f-5a81-4347-8540-fe3359badc30", "page": 2, "type": "paragraph", "text": "A\ufb02uria. Among subjects aged 65 years and older, 642 received Flublok and 648 received"}
{"id": "4486aa08-940c-4b25-9d58-d1a10d919029", "page": 2, "type": "paragraph", "text": "A\ufb02uria."}
{"id": "2f6b85b8-9004-463c-baff-270f16cfe9bf", "page": 2, "type": "paragraph", "text": "In a clinical trial of adults 18-49 years of age (Study 1, Table 1) the mean age of"}
{"id": "9eab5f25-48d5-4cb1-b5f7-919e6d9d06b7", "page": 2, "type": "paragraph", "text": "participants was 32.5 years, 59% were female, and 67% were Caucasian (see Clinical"}
{"id": "d6e01fa1-2254-425a-a3fc-2a76205ce133", "page": 2, "type": "paragraph", "text": "Studies [14.1])."}
{"id": "75d319d6-7ea9-4fd7-a4e7-3a93d82342dd", "page": 2, "type": "paragraph", "text": "Table 1: Frequency of Solicited Local Injection Site Adverse Reactions and"}
{"id": "8d988682-6444-486c-b938-bd9ecef6da7e", "page": 2, "type": "paragraph", "text": "Systemic Adverse Reactions within 7 Days of Administration of Flublok or"}
{"id": "523944f7-78ae-4e49-ade0-35a5c7ed6363", "page": 2, "type": "paragraph", "text": "Placebo in Adults 18-49 Years of Age, Study 1, Total Vaccinated Cohort*,\u2020,\u2021"}
{"id": "410eab8f-d3e0-4574-a228-15ab19ace753", "page": 2, "type": "paragraph", "text": "Flublok"}
{"id": "9e28fe18-5237-4340-ac82-1ffc78bcab20", "page": 2, "type": "paragraph", "text": "N=2272"}
{"id": "098f45f6-90d9-475b-9d86-65cecae761b8", "page": 2, "type": "paragraph", "text": "Placebo"}
{"id": "39db6873-5632-4a07-987c-eab8573dae2f", "page": 2, "type": "paragraph", "text": "N=2231"}
{"id": "2e311e0d-13d1-4911-a366-4649bce10608", "page": 2, "type": "paragraph", "text": "Local"}
{"id": "ac55b143-226a-4bc6-82fe-0a184cdf38b0", "page": 2, "type": "paragraph", "text": "%"}
{"id": "86a5f861-2308-4778-9253-b61175a34944", "page": 2, "type": "paragraph", "text": "%"}
{"id": "3c9d814d-e80e-46c5-884f-5c197628ea93", "page": 2, "type": "paragraph", "text": "Any"}
{"id": "19be8aef-3923-4e3a-8913-1ad273b31011", "page": 2, "type": "paragraph", "text": "Mod\u00a7"}
{"id": "bf6812ca-b84d-42ac-82cb-be65a0eebbd1", "page": 2, "type": "paragraph", "text": "Sev\u00a7"}
{"id": "404d93b0-7236-4362-89a8-11b2d1b6a6ee", "page": 2, "type": "paragraph", "text": "Any"}
{"id": "316bd678-7de1-4715-9c58-ba2d693ce22d", "page": 2, "type": "paragraph", "text": "Mod\u00a7"}
{"id": "b7b6da1b-c9ee-42be-b5e5-32b9531d341e", "page": 2, "type": "paragraph", "text": "Sev\u00a7"}
{"id": "67ae33eb-e66b-45ca-9edf-1516f0358551", "page": 2, "type": "paragraph", "text": "Pain"}
{"id": "82d22f3b-f792-4330-972c-6183a98a2108", "page": 2, "type": "paragraph", "text": "37"}
{"id": "c75968c5-d821-4922-979b-b87fdcaaf8c4", "page": 2, "type": "paragraph", "text": "2"}
{"id": "0b5096f1-03f5-401c-b945-30cbbf5cd384", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "f5e367bd-7c38-449c-a3ac-0f9fd621536b", "page": 2, "type": "paragraph", "text": "8"}
{"id": "67b0ce4f-becf-49a0-9fea-9154b1a07640", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "6952de0b-05da-4ff1-aa4f-f2f2ce8d2be2", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "634738c1-8781-484c-b283-221993c361c0", "page": 2, "type": "paragraph", "text": "Redness"}
{"id": "2c11ec6e-6477-4fcc-9e31-e63834c91ee8", "page": 2, "type": "paragraph", "text": "4"}
{"id": "b891a93a-3c24-4c19-897b-1905fd138f16", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "de788b5f-ab4b-4fd5-8553-dcbd7437657a", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "d150f685-5d5d-4a0e-b36e-95811b7702f7", "page": 2, "type": "paragraph", "text": "2"}
{"id": "732973f4-35f5-4751-8f2b-8683800106b7", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "50de50ed-eb5d-469e-bd3d-90b42dc91926", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "8c4ee733-73c0-4046-88ad-a81b1a1b7c9b", "page": 2, "type": "paragraph", "text": "Swelling"}
{"id": "e8b9227e-e32f-43b3-bb5b-9b3a5d7979d9", "page": 2, "type": "paragraph", "text": "3"}
{"id": "db8e1f0d-cd74-4537-a1ac-eccfac480c38", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "5d176cd2-7b69-4986-934b-e231655cf43d", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "844923e5-3210-4e81-a41c-ac6e8f45b648", "page": 2, "type": "paragraph", "text": "2"}
{"id": "8293a8e3-944c-45b4-abfe-de3c7d643c56", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "a862ba4c-c92e-4a71-a9d7-c04ef93a78a7", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "1dc74853-edee-47c2-964c-3d66d7a51bce", "page": 2, "type": "paragraph", "text": "Bruising"}
{"id": "da7b65e0-9f18-41e0-bd5f-6ae9aa89822a", "page": 2, "type": "paragraph", "text": "3"}
{"id": "eda4fb5c-58a5-4f19-b190-27abeb8ff751", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "5d4a3b8d-ac77-4027-804c-75c4b2cc59ce", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "64fcfd47-39a6-471b-af6d-c0cd556db2cc", "page": 2, "type": "paragraph", "text": "3"}
{"id": "ada8c199-2c59-4e92-b1a8-955b4f64df7d", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "733441da-789a-49a4-b65d-c0dca9b656b1", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "76a03fcc-d4ca-4741-8ce8-4018b0796f4e", "page": 2, "type": "paragraph", "text": "Systemic"}
{"id": "32928866-0d3d-4876-94d9-c086212c592c", "page": 2, "type": "paragraph", "text": "%"}
{"id": "9cde46c3-22d4-4b4b-b5e5-babeaa623d7b", "page": 2, "type": "paragraph", "text": "%"}
{"id": "b10f631d-d65e-4b00-9f88-2faa525ac365", "page": 2, "type": "paragraph", "text": "Headache"}
{"id": "8398b471-eb7c-4736-9bb6-eadb300b48ce", "page": 2, "type": "paragraph", "text": "15"}
{"id": "3b4b30ea-8ef4-4fe1-8a11-ffbeed8be4f1", "page": 2, "type": "paragraph", "text": "3"}
{"id": "8a1bde00-117b-41bd-810f-852d0de13e0a", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "d6915531-73c3-4ed8-99d6-b96916fcfe9c", "page": 2, "type": "paragraph", "text": "16"}
{"id": "38149eb5-1768-4bed-9f48-d0acf4994a11", "page": 2, "type": "paragraph", "text": "3"}
{"id": "27024a7a-633e-41fa-b5f2-295a1687e9f1", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "58bf0491-45ec-451c-a216-9f53f9a838ba", "page": 2, "type": "paragraph", "text": "Fatigue"}
{"id": "708212a4-6f7c-42f8-b1f6-a6c239ddb0e9", "page": 2, "type": "paragraph", "text": "15"}
{"id": "298fd26d-681d-437b-b73f-aa754646323e", "page": 2, "type": "paragraph", "text": "3"}
{"id": "47dadac5-2c45-447b-bfee-9c2d5ecbee23", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "065c0647-8992-4aef-beee-ea8fc348365a", "page": 2, "type": "paragraph", "text": "14"}
{"id": "eb122c44-81e8-438b-89ee-f38e036004c4", "page": 2, "type": "paragraph", "text": "3"}
{"id": "976bb624-1248-4e81-b93f-5b0eb9b536c6", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "2076b049-f97f-446a-bdcb-9727157fab0c", "page": 2, "type": "paragraph", "text": "Muscle Pain"}
{"id": "c2fd5d5d-ae91-4840-80d7-712ef0f6f840", "page": 2, "type": "paragraph", "text": "11"}
{"id": "6766c129-39b3-41d2-aca1-fd020b752753", "page": 2, "type": "paragraph", "text": "2"}
{"id": "b2c68f12-6ac8-4899-93c0-ccdde45a1b94", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "ee1c634c-d5d3-40f9-a947-63784de7d086", "page": 2, "type": "paragraph", "text": "7"}
{"id": "6e5f8d74-e7a8-41cc-9b4c-fcec550a5bc1", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "6bb7fded-fdec-42d7-9f7d-6e5b7652fefc", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "2b805942-b019-48a7-9352-c92f5025a092", "page": 2, "type": "paragraph", "text": "Nausea"}
{"id": "2b76d931-4dc4-4535-afbe-31205e89f214", "page": 2, "type": "paragraph", "text": "6"}
{"id": "9adb662e-24c1-4a3d-b9ce-dea0fa412a0e", "page": 2, "type": "paragraph", "text": "1"}
{"id": "6970cbb7-5c52-4b81-b5a5-6b259f068128", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "611e0de2-7c7d-4e0b-a625-14903c09bd71", "page": 2, "type": "paragraph", "text": "5"}
{"id": "01bac0f9-0357-4e3e-a197-4c0a0d352a7d", "page": 2, "type": "paragraph", "text": "1"}
{"id": "1428fc62-6a60-46df-8c53-182ead29a07b", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "96d52670-fc5b-4f60-8082-ee8fc2831cc6", "page": 2, "type": "paragraph", "text": "Joint pain"}
{"id": "6aef9b80-9c13-4bb5-9409-4036d554edce", "page": 2, "type": "paragraph", "text": "4"}
{"id": "c2a7323e-5c7b-4d38-a99e-81b5c45f5a2f", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "a63dbad7-2d72-4e88-a7ea-b3319ecec6c6", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "afd90110-6d22-4f90-af3a-05123e00f484", "page": 2, "type": "paragraph", "text": "4"}
{"id": "87752b2d-ee86-41cd-93e5-07cbd4f935c9", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "798c4295-2edd-4c29-b6f7-4a4077f3dec3", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "4b9b09d9-cbd4-4275-b12e-0d22b2a006dd", "page": 2, "type": "paragraph", "text": "Chills"}
{"id": "a3cb5d6d-0162-43ef-9b8e-3ce604f1d4ce", "page": 2, "type": "paragraph", "text": "3"}
{"id": "8e6756d1-f7c9-4265-a4ce-423463fa9c5a", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "3ddd182f-4a58-4d17-a6dd-a6385689cce9", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "1605f76c-f032-4d70-a405-b6aad69070af", "page": 2, "type": "paragraph", "text": "3"}
{"id": "e52139b8-5dcc-4bb0-8b7b-52113dc967f9", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "0db5ac94-ef2b-48cb-9228-b928cac18166", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "048d2077-a91b-43fd-bd96-27e468d42978", "page": 2, "type": "paragraph", "text": "Fever\u00b6"}
{"id": "d7619a30-e8be-4074-84d6-f6e51531482c", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "4bde6c06-9b38-4149-ad62-d351953a8f26", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "d1c02a63-f164-463d-a03b-cd8349e39f5d", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "9a43e578-0ba7-4e8e-af2f-ef736e1f18bb", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "e4afd745-31e8-4860-8d7e-ef5f5780c73b", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "4b23a7c4-2b01-403d-85ec-3f90f8a299d7", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "3d60f585-33ff-49d0-8cf3-68d34ad4bf9d", "page": 2, "type": "paragraph", "text": "NOTE: Data based on the most severe response reported by subjects. Results \u22651%"}
{"id": "941462f4-8e51-4420-b13e-1fe066a5309f", "page": 2, "type": "paragraph", "text": "reported to nearest whole percent; results >0 but <1% reported as <1%."}
{"id": "c572e2f8-87ae-4718-94eb-96d374d6ecba", "page": 2, "type": "paragraph", "text": "*Total Vaccinated Cohort is de\ufb01ned as all randomized subjects who received study vaccine"}
{"id": "83276dc0-4843-4815-805e-8eeed27ae042", "page": 2, "type": "paragraph", "text": "according to the treatment actually received and who provided data."}
{"id": "56ddafe1-6743-49af-b69d-b589909138bb", "page": 2, "type": "paragraph", "text": "\u2020Study 1 is registered as NCT00539981 under the National Clinical Trials registry."}
{"id": "8e12cfc5-ff1b-49c0-a020-ef98ad2b4800", "page": 2, "type": "paragraph", "text": "\u2021Denominators for Study 1: The total number of enrolled, randomized, and vaccinated"}
{"id": "b080f887-4d45-4eb4-9e8e-80848d167662", "page": 2, "type": "paragraph", "text": "subjects was 2344 in the Flublok group and 2304 in the placebo group. For all categories"}
{"id": "034f7e3e-02c5-452a-90d2-353e3ab27a14", "page": 2, "type": "paragraph", "text": "except fever, the number of subjects with missing values was 72 in the Flublok group"}
{"id": "5b679915-45f4-4cde-8361-ab033b602fc1", "page": 2, "type": "paragraph", "text": "and 73 in the Placebo group so that these denominators are 2272 and 2231 respectively."}
{"id": "f8e90829-d358-46ce-beef-195f868bfe11", "page": 2, "type": "paragraph", "text": "For fever, 89 Flublok recipients and 104 Placebo recipients were missing data, making"}
{"id": "a708be66-83e9-47e5-9184-9bbc558f2591", "page": 2, "type": "paragraph", "text": "these denominators 2255 and 2200 respectively."}
{"id": "bc6063b1-840c-48b0-89b9-ec1d894aa6e2", "page": 2, "type": "paragraph", "text": "\u00a7Moderate = had it, and it was bad enough to prevent a signi\ufb01cant part of usual activities;"}
{"id": "cc8bd0cb-2627-45d0-844a-96303953db83", "page": 2, "type": "paragraph", "text": "Severe = had it, and it prevented most or all of normal activities, or had to see a doctor"}
{"id": "5e860769-8e6a-43a1-b044-20fc6d4aac5d", "page": 2, "type": "paragraph", "text": "for prescription medicine."}
{"id": "3b8ce60f-dc9e-47d3-91b0-d54ef89efcc5", "page": 2, "type": "paragraph", "text": "\u00b6Fever de\ufb01ned as \u2265100.4\u00b0F (38\u00b0C). Mild (\u2265100.4\u00b0 to <101.1\u00b0F); Moderate (\u2265101.2\u00b0F to"}
{"id": "5a64337b-20a1-45b7-af62-2e89a85bdd9d", "page": 2, "type": "paragraph", "text": "<102.2\u00b0F); Severe (\u2265102.2\u00b0F)"}
{"id": "007b752b-635c-4d80-818c-c5c514b04565", "page": 2, "type": "paragraph", "text": "Across three clinical trials (Studies 2 \u2013 4, Tables 2 and 3) a total of 2050 adults age 50"}
{"id": "a6f86ae7-6bd0-4dc7-9c1b-18adc63ba291", "page": 2, "type": "paragraph", "text": "years and older received Flublok and 2048 received a U.S.-licensed trivalent inactivated"}
{"id": "68403d87-7343-4414-949b-341aab4a2b63", "page": 2, "type": "paragraph", "text": "in\ufb02uenza vaccine (IIV3) comparator. The mean age of Flublok study participants was 65"}
{"id": "66ec0fb3-8d48-4280-b976-02b5abe82a91", "page": 2, "type": "paragraph", "text": "years; 56% were female and 80% were Caucasian."}
{"id": "7f7f3d28-fed0-4885-ba65-6ccba6478475", "page": 2, "type": "paragraph", "text": "The incidence of solicited reactogenicity differed between adults 50 through 64 years of"}
{"id": "815657a8-160a-491c-90d7-513503c537fc", "page": 2, "type": "paragraph", "text": "age and adults aged 65 years and older. Therefore, data from Studies 2, 3, and 4 were"}
{"id": "59e20c73-fd05-4166-9807-1991440bb214", "page": 2, "type": "paragraph", "text": "pooled according to age group and are presented separately (Tables 2 and 3)."}
{"id": "52bc0215-6af0-4fe4-a519-12f60e5e0dab", "page": 2, "type": "paragraph", "text": "Most adverse reactions in both age groups were mild in severity."}
{"id": "6199e5a3-e7f3-4e5b-b527-8239cca7e331", "page": 2, "type": "paragraph", "text": "Table 2: Frequency of Solicited Local Injection Site Adverse Reactions and"}
{"id": "22fa1aae-713f-4368-932a-47abf3b6c19a", "page": 2, "type": "paragraph", "text": "Systemic Adverse Reactions within 7 Days of Administration of Flublok or"}
{"id": "cbe729b6-e11c-4454-9679-96cb9d93bd2a", "page": 2, "type": "paragraph", "text": "Comparator in Adults 50-64 Years of Age, Studies 2 and 4, Total Vaccinated"}
{"id": "3c2bbb34-32d4-4774-b92c-fc89eeabc80f", "page": 2, "type": "paragraph", "text": "Cohort*,\u2020"}
{"id": "3159fdc6-69b7-4f29-ae98-5d9da4e2b457", "page": 2, "type": "paragraph", "text": "Flublok"}
{"id": "7cc2f01a-76a3-4dc9-8493-70a4e21b5a2d", "page": 2, "type": "paragraph", "text": "N=972"}
{"id": "97c0db70-46af-4a66-b645-bd6edb0063f0", "page": 2, "type": "paragraph", "text": "IIV3\u2020"}
{"id": "2f4761b4-9de7-44b4-b960-aa52f58e96b8", "page": 2, "type": "paragraph", "text": "N=967"}
{"id": "22a418da-fd8b-4c44-9c84-310c76d28755", "page": 2, "type": "paragraph", "text": "Any"}
{"id": "0a50d471-3bd8-4455-826f-2a499106a28f", "page": 2, "type": "paragraph", "text": "Mod\u2021"}
{"id": "ad44d716-e677-4b24-88c5-c56f6ec56400", "page": 2, "type": "paragraph", "text": "Sev\u2021"}
{"id": "600a9d08-8e9b-47db-b828-043f418aa39c", "page": 2, "type": "paragraph", "text": "Any"}
{"id": "8ae181d0-6865-4c2b-a0b2-49fbdd38fe3e", "page": 2, "type": "paragraph", "text": "Mod\u2021"}
{"id": "bce423bf-f622-4c1a-baca-b23dbe68c795", "page": 2, "type": "paragraph", "text": "Sev\u2021"}
{"id": "b2abe908-07a8-4098-939a-993fa7ca238c", "page": 2, "type": "paragraph", "text": "Local"}
{"id": "0b961c4a-2339-422f-96f5-79e81b6c149b", "page": 2, "type": "paragraph", "text": "%"}
{"id": "8902b294-ef7b-4571-b5f6-fc8a7191b0a2", "page": 2, "type": "paragraph", "text": "Pain"}
{"id": "c7cbddd8-9f5d-47c5-b210-0ab964b81c60", "page": 2, "type": "paragraph", "text": "32"}
{"id": "4e2f7256-24a2-45c0-8e5c-1509372e01af", "page": 2, "type": "paragraph", "text": "2"}
{"id": "1b0f10e6-d827-4640-b841-2b444b5e842d", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "c9743532-acab-4763-a14b-b58df242cc22", "page": 2, "type": "paragraph", "text": "37"}
{"id": "7cf22943-b1dd-427f-80ef-4cd2248962ec", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "8a78d565-7af1-49b5-8324-8aaf420a2f29", "page": 2, "type": "paragraph", "text": "0"}
{"id": "fa987eab-00d6-4447-a020-bc4d1fce4173", "page": 2, "type": "paragraph", "text": "Firmness/Swelling"}
{"id": "e6c8ec24-946d-4669-8956-ff8fde239ba1", "page": 2, "type": "paragraph", "text": "7"}
{"id": "3c535f79-7c96-459f-ab7d-316a4691da9e", "page": 2, "type": "paragraph", "text": "2"}
{"id": "6f075d59-3592-44d7-b97d-c7bb80820790", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "0cb8f6cc-a195-4894-bb0f-5370a0a903f4", "page": 2, "type": "paragraph", "text": "6"}
{"id": "080e2918-67af-45eb-a630-b1b6da5e9584", "page": 2, "type": "paragraph", "text": "1"}
{"id": "efd9d383-bfb0-4c3f-abd0-718ab9191868", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "bb57d4e8-7555-4d90-8315-8b5dd889a1f0", "page": 2, "type": "paragraph", "text": "Redness"}
{"id": "3c5d2eb3-de1d-44cd-8729-8371d13eb17f", "page": 2, "type": "paragraph", "text": "6"}
{"id": "fa7dfbb0-9c55-4e2f-9309-d1bfac585405", "page": 2, "type": "paragraph", "text": "2"}
{"id": "5608f158-a9b1-4422-a0e3-7ff820dcf2bc", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "e6ce6a85-d112-4eef-bbdb-eb77d3fba0a7", "page": 2, "type": "paragraph", "text": "5"}
{"id": "8ac573bd-e574-42e4-8e1c-a2075614e529", "page": 2, "type": "paragraph", "text": "1"}
{"id": "79427acc-5412-4d40-96b0-ece780820e95", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "f00f2de7-4b4c-413d-80c0-d33a40787b2b", "page": 2, "type": "paragraph", "text": "Systemic"}
{"id": "d60805b9-5a68-4a1f-b199-5c4b0cdb1ec1", "page": 2, "type": "paragraph", "text": "%"}
{"id": "7c4c2349-3df4-4683-b645-5d6bf43d0303", "page": 2, "type": "paragraph", "text": "Headache"}
{"id": "1ec9b96c-8a4e-445e-8faf-5cbd2c872dd5", "page": 2, "type": "paragraph", "text": "17"}
{"id": "f2579937-bab6-4733-ba7d-1a2807f8fbcd", "page": 2, "type": "paragraph", "text": "4"}
{"id": "9ed20b8a-edca-4fb9-8108-33ae13d418e3", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "53365033-8db6-4669-ba96-9f96cce8b44d", "page": 2, "type": "paragraph", "text": "16"}
{"id": "7fd6755a-0037-4d9c-a4dc-94b82b624c0e", "page": 2, "type": "paragraph", "text": "3"}
{"id": "5605f048-5f96-437e-b0aa-117caef9c2d2", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "dd65d9f0-5585-4a04-88c0-41d4b180822c", "page": 2, "type": "paragraph", "text": "Fatigue"}
{"id": "fa4e16a2-1b7e-455d-9f5c-c1a6e7586d69", "page": 2, "type": "paragraph", "text": "13"}
{"id": "2c9d6389-2000-4943-a3d9-85611c8c160c", "page": 2, "type": "paragraph", "text": "3"}
{"id": "f575decf-b9f3-4acd-a67e-51bc9358f878", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "047c0cd1-f56d-4d56-89b3-4189941f206e", "page": 2, "type": "paragraph", "text": "17"}
{"id": "5c333bd9-bed9-4cf5-939e-342c728a9d89", "page": 2, "type": "paragraph", "text": "3"}
{"id": "e11a0527-a855-4fed-af49-5d150fa25c22", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "9e4e4ead-5cdc-4095-bb8f-0bc03477aa60", "page": 2, "type": "paragraph", "text": "Muscle Pain"}
{"id": "a5ab4ff0-d7c3-4b09-af18-1240f659dc0d", "page": 2, "type": "paragraph", "text": "11"}
{"id": "d8c54956-62a2-49e7-95cb-7042b0f2a5bc", "page": 2, "type": "paragraph", "text": "2"}
{"id": "421777a7-cb45-4b2e-b0c9-f8788ef9bc9e", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "9c2ba4f9-0822-48dd-b837-bd26291a29a7", "page": 2, "type": "paragraph", "text": "11"}
{"id": "86f55d77-37a4-49c3-ae21-a33824469d59", "page": 2, "type": "paragraph", "text": "2"}
{"id": "d543d2d9-7262-44fe-9f14-5c207c56e456", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "a88eac8f-df30-48f1-80c1-9eeef4f07a9f", "page": 2, "type": "paragraph", "text": "Joint Pain"}
{"id": "9e0957ca-23e7-41fd-ac0c-377f3ca65fdf", "page": 2, "type": "paragraph", "text": "8"}
{"id": "522dbd2e-1fc2-4ee9-8d1a-1b4cc6c18ca0", "page": 2, "type": "paragraph", "text": "2"}
{"id": "244b284c-1b77-41d4-96b0-bacb1eed1cbb", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "80a5cc9f-969a-41af-bf04-3acce2178acb", "page": 2, "type": "paragraph", "text": "8"}
{"id": "1817a937-d0a0-4024-9e02-b85ea8832c1f", "page": 2, "type": "paragraph", "text": "2"}
{"id": "4b50813c-6971-4a5b-b469-02f8896195d5", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "3f982885-8e61-4cd8-acbf-6a2d8c852b89", "page": 2, "type": "paragraph", "text": "Nausea"}
{"id": "99a662ca-829d-4750-9c2f-c7730900c527", "page": 2, "type": "paragraph", "text": "6"}
{"id": "625ee38b-25e9-42ee-9ed8-5e608a18c8ce", "page": 2, "type": "paragraph", "text": "1"}
{"id": "7375830a-6339-4cc1-9605-799b5c1e96ef", "page": 2, "type": "paragraph", "text": "0"}
{"id": "412f2ddb-3fbe-4d93-80f1-3e0ce609e82f", "page": 2, "type": "paragraph", "text": "5"}
{"id": "ce9ba07f-c641-4b40-80d8-7ee5f6623bd1", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "68b098ba-811c-4f07-8adf-3a75b9a56bb7", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "9eca1ee4-50a1-4b90-9b3c-cd43345a1507", "page": 2, "type": "paragraph", "text": "Shivers/Chills"}
{"id": "f8d94ff2-2497-4fff-bcfb-4de043cbbed1", "page": 2, "type": "paragraph", "text": "5"}
{"id": "b2bf0b09-942b-4601-9f63-a7eb69e60fb4", "page": 2, "type": "paragraph", "text": "1"}
{"id": "9939f9ee-8983-441f-aeb3-9ad214f654e2", "page": 2, "type": "paragraph", "text": "0"}
{"id": "53cced39-e4c7-44d1-b389-23b3f0bfb355", "page": 2, "type": "paragraph", "text": "4"}
{"id": "4f0dbb3e-2c45-4628-983a-4880bc4331ab", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "0ebafa89-4aa5-4b13-b84f-7153400cecd2", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "7d8810ba-6b35-4f70-8552-008f6a61bf1c", "page": 2, "type": "paragraph", "text": "Fever\u00a7"}
{"id": "c7f92b91-4357-4b58-ba51-d231d4830209", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "3dd78617-bb62-45d9-bd61-0cdf8dab1b17", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "a018ac3c-20b2-4159-ad29-8481379c0599", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "1771238f-1f95-426f-b7ae-c64150029c33", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "6db061b5-2e92-4801-bcfd-ad1d24244108", "page": 2, "type": "paragraph", "text": "0"}
{"id": "5fd5be11-5955-499a-895a-adb1e26cc9bc", "page": 2, "type": "paragraph", "text": "0"}
{"id": "67206f11-240a-4b20-8d08-35880fc5f054", "page": 2, "type": "paragraph", "text": "NOTE: Data based on the most severe response reported by subjects. Results \u22651%"}
{"id": "2c9ebe4e-7698-44be-a9c6-7ddd1efab1f8", "page": 2, "type": "paragraph", "text": "reported to nearest whole percent; results >0 but <1% reported as <1%."}
{"id": "e2aa9e0b-651d-4afa-9237-ddbb3798381a", "page": 2, "type": "paragraph", "text": "*Total Vaccinated Cohort is de\ufb01ned as all randomized subjects who received study vaccine"}
{"id": "72789049-13d1-4f74-913b-cefd6d4cecb1", "page": 2, "type": "paragraph", "text": "according to the treatment actually received and who provided data."}
{"id": "63fda3f0-06c1-4218-b819-fd2f071586ba", "page": 2, "type": "paragraph", "text": "\u2020Pooled Data from Studies 2 and 4. For Studies 2 and 4, the U.S.-licensed IIV3"}
{"id": "bc3d49d1-86ee-4283-95b4-57264b0399f2", "page": 2, "type": "paragraph", "text": "comparators were Fluzone and A\ufb02uria, respectively. Studies 2 and 4 are registered as"}
{"id": "f30197d4-6e3c-457d-9a56-075bbc24a698", "page": 2, "type": "paragraph", "text": "NCT00539864 and NCT01825200, respectively, under the National Clinical Trials"}
{"id": "7c55c523-9a09-4035-bb99-a6cd98b5c2d3", "page": 2, "type": "paragraph", "text": "registry."}
{"id": "bac0dd1d-d59d-4295-9768-05df731bbcfc", "page": 2, "type": "paragraph", "text": "\u2021Moderate = had it, and it was bad enough to prevent a signi\ufb01cant part of usual activities;"}
{"id": "7ff1fea7-95cf-402b-ac90-8bc2011e696f", "page": 2, "type": "paragraph", "text": "Severe = had it, and it prevented most or all of normal activities, or had to see a doctor"}
{"id": "3d5e1dca-3610-4511-8450-6810baa935d1", "page": 2, "type": "paragraph", "text": "for prescription medicine."}
{"id": "6fa60cd2-16c2-4003-a470-9484ff51c270", "page": 2, "type": "paragraph", "text": "\u00a7Fever de\ufb01ned as \u2265100.4\u00b0F (38\u00b0C). Mild (\u2265100.4\u00b0 to <101.1\u00b0F); Moderate (\u2265101.2\u00b0F to"}
{"id": "59decf1f-d345-4f11-84cd-b280497d6326", "page": 2, "type": "paragraph", "text": "<102.2\u00b0F); Severe (\u2265102.2\u00b0F) For fever, 12 Flublok recipients and 5 IIV3 recipients were"}
{"id": "69880495-8f67-4433-a484-895a822859c7", "page": 2, "type": "paragraph", "text": "missing data, making these denominators 964 and 962, respectively."}
{"id": "d30b575b-fec0-4d70-a511-950243d48fdf", "page": 2, "type": "paragraph", "text": "Table 3: Frequency of Solicited Local Injection Site Adverse Reactions and"}
{"id": "4c3c588b-ff48-47ad-8c0d-27a88bfbb826", "page": 2, "type": "paragraph", "text": "Systemic Adverse Reactions within 7 Days of Administration of Flublok or"}
{"id": "620f1c16-7ba4-4263-9f10-18d8821d3ca3", "page": 2, "type": "paragraph", "text": "Comparator in Adults \u226565 Years of Age, Studies 3 and 4, Total Vaccinated"}
{"id": "42cbc7b7-a079-49fe-9f87-c9b28a968f21", "page": 2, "type": "paragraph", "text": "Cohort *,\u2020"}
{"id": "7c7f2974-dc6a-40e3-b339-bb34b524a9d9", "page": 2, "type": "paragraph", "text": "Flublok"}
{"id": "3ec674b0-b0c1-4a1f-8d3a-c3b0f54e1d92", "page": 2, "type": "paragraph", "text": "N=1078"}
{"id": "a565d126-5729-4ef5-a9cd-14de9d0313ae", "page": 2, "type": "paragraph", "text": "IIV3\u2020"}
{"id": "7bdd45da-783d-4627-a9f5-e998f6e676b5", "page": 2, "type": "paragraph", "text": "N=1081"}
{"id": "d0ba9b27-d155-48b4-af53-dea4dd4c5f36", "page": 2, "type": "paragraph", "text": "Any"}
{"id": "412ea6aa-b382-498e-a0f7-1bf96a04aaa0", "page": 2, "type": "paragraph", "text": "Mod\u2021"}
{"id": "15abcfe9-a140-4855-91b9-1c5f70d2c306", "page": 2, "type": "paragraph", "text": "Sev\u2021"}
{"id": "7f913563-ebe8-479c-bd7b-5601dab08d42", "page": 2, "type": "paragraph", "text": "Any"}
{"id": "e235aecd-fd21-44cb-b83d-9fb78e5d03fc", "page": 2, "type": "paragraph", "text": "Mod\u2021"}
{"id": "cb0aee02-5525-406c-894d-52fe3fe59358", "page": 2, "type": "paragraph", "text": "Sev\u2021"}
{"id": "01d9b3fd-daf7-4606-b195-5a75bfefe74d", "page": 2, "type": "paragraph", "text": "Local"}
{"id": "5437bed0-505b-454e-9ae1-94a59047f06c", "page": 2, "type": "paragraph", "text": "%"}
{"id": "b5ffa335-ba5a-456b-b085-822c62e9ed02", "page": 2, "type": "paragraph", "text": "Pain"}
{"id": "747eb0e9-5834-4229-a4b6-d2ce91044ee1", "page": 2, "type": "paragraph", "text": "19"}
{"id": "1ceb432e-2cab-45ed-a11d-09b7b4b27bb4", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "719f97a8-f964-4308-aecf-a9b4ed1fd006", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "04cea3a9-c805-4aa8-bfbd-a9d9d0b2c68b", "page": 2, "type": "paragraph", "text": "20"}
{"id": "f24ed0c6-18d3-42ab-adfb-88882193999d", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "112491b8-8d92-48c3-8eb1-60d96b046b6c", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "a2d5efde-0724-45f6-b376-bb111ea1b252", "page": 2, "type": "paragraph", "text": "Redness"}
{"id": "8d76b169-68e7-4c30-bf41-d208241c44d3", "page": 2, "type": "paragraph", "text": "7"}
{"id": "3b2eef16-f97b-453a-a7f0-39c5a6038116", "page": 2, "type": "paragraph", "text": "1"}
{"id": "aa0b2056-58c0-4c37-8bdf-c021d78245eb", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "bbd354bd-7b2a-4153-b247-bc0521710e6a", "page": 2, "type": "paragraph", "text": "7"}
{"id": "c26addb1-e1f5-4624-81bf-7e569c72bb1f", "page": 2, "type": "paragraph", "text": "1"}
{"id": "31808eae-77b3-44a7-822c-9db445de5627", "page": 2, "type": "paragraph", "text": "1"}
{"id": "ce6bd47c-c00d-46a4-859b-34c74ffcd285", "page": 2, "type": "paragraph", "text": "Firmness/Swelling"}
{"id": "7a2062de-f001-4de1-a20a-0103e9f101b0", "page": 2, "type": "paragraph", "text": "7"}
{"id": "d6dd0bf5-6f5f-49d7-9428-8c034e97c55c", "page": 2, "type": "paragraph", "text": "2"}
{"id": "a7d4580b-ba4d-49bb-8a5a-93238f6387ed", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "1fcd7caf-f9fd-4e36-a5bb-d64e4423169c", "page": 2, "type": "paragraph", "text": "7"}
{"id": "3c87b650-5ee4-45a6-a68d-f4b042d87c46", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "cc49d481-3ce3-49c4-a8ff-af5433b5ab23", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "03a1c558-21d5-4030-bc83-f9795ccb9c91", "page": 2, "type": "paragraph", "text": "Systemic"}
{"id": "11dffbcb-3ece-4cb9-898f-e79870021d27", "page": 2, "type": "paragraph", "text": "%"}
{"id": "2b30228e-21ff-4c16-8ce1-486dc8988a56", "page": 2, "type": "paragraph", "text": "Fatigue"}
{"id": "59285fa0-93fe-4b1f-b0d9-63638fdcdec0", "page": 2, "type": "paragraph", "text": "13"}
{"id": "acebff21-cca7-4085-a78b-2f9e2dbab573", "page": 2, "type": "paragraph", "text": "3"}
{"id": "7c1e14f4-1210-416f-8f71-6f7db59d2d3a", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "56c2feb5-22b9-4dee-8a6a-d3daf9688401", "page": 2, "type": "paragraph", "text": "15"}
{"id": "5014f6ac-c7ed-4aa7-9542-21470439e2d4", "page": 2, "type": "paragraph", "text": "2"}
{"id": "3e72ef34-30ad-4564-8b49-50355072d2cd", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "5a381fc8-1052-42e7-86a0-e8c6d7f7e310", "page": 2, "type": "paragraph", "text": "Headache"}
{"id": "2b2a758a-7550-400b-b588-6b62817e3af4", "page": 2, "type": "paragraph", "text": "10"}
{"id": "11725bea-1fdf-4c43-a74f-ca0e0111e81c", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "e9021b08-30f2-4336-ac5d-6054b08820ca", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "f8dc8c32-1582-4c2b-a9a2-45b8d7df0dcf", "page": 2, "type": "paragraph", "text": "9"}
{"id": "e4c543c1-5a58-457e-910d-960c757225b1", "page": 2, "type": "paragraph", "text": "1"}
{"id": "621bbe50-4f9c-4ca2-b6a8-23c88a419925", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "fc4ee665-472b-4f19-8b75-9da87adc0452", "page": 2, "type": "paragraph", "text": "Muscle Pain"}
{"id": "10f4a883-69a1-42bd-baf6-c7c376fef0d5", "page": 2, "type": "paragraph", "text": "8"}
{"id": "804dc5c4-1478-42b5-a2de-91e11b98b0e8", "page": 2, "type": "paragraph", "text": "2"}
{"id": "fd60af77-6d33-4556-898b-3913a45d5f59", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "231ae4ef-b8f5-4df5-aaf9-a70f7f5cbab0", "page": 2, "type": "paragraph", "text": "8"}
{"id": "83c02f2f-5051-418f-8228-53952cbfc2b3", "page": 2, "type": "paragraph", "text": "1"}
{"id": "93503e5e-c553-4809-89be-965814e6388f", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "203e3f4a-9b4e-4076-bef5-868bdc06cf40", "page": 2, "type": "paragraph", "text": "Joint Pain"}
{"id": "62773206-075d-41aa-ba9d-6ef660a02f2a", "page": 2, "type": "paragraph", "text": "6"}
{"id": "f9c1a816-6ed9-406b-aaf1-b7448b842f9b", "page": 2, "type": "paragraph", "text": "1"}
{"id": "d2be963e-69eb-4fb9-b706-409fcfc2b3e1", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "45396c4e-ddc4-4f4f-9167-3190e5702cd3", "page": 2, "type": "paragraph", "text": "6"}
{"id": "e157fa11-9617-4255-9065-5c10fe85b57b", "page": 2, "type": "paragraph", "text": "1"}
{"id": "5fdcc0dc-c829-44f3-b603-c0c08df377e6", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "f2970528-d25d-42fb-943c-c58a1aa822ee", "page": 2, "type": "paragraph", "text": "Shivers/Chills"}
{"id": "4e9577c4-c89d-4b73-a6fc-174c369fff40", "page": 2, "type": "paragraph", "text": "5"}
{"id": "8511cd7f-833f-4c80-8b93-8db743b48c7d", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "b5789fde-aade-4676-8c3e-be97cbe1292f", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "71904fb8-f16f-4888-9322-1507fed69fff", "page": 2, "type": "paragraph", "text": "5"}
{"id": "ba75d866-066e-49fb-98a1-5a423107f812", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "3ac2a869-a336-43f3-9f89-5fdc3c0d27f9", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "a0a49581-8947-4103-8052-ea25d4164ecf", "page": 2, "type": "paragraph", "text": "Nausea"}
{"id": "46526494-e2aa-4b37-9230-178edb83c372", "page": 2, "type": "paragraph", "text": "4"}
{"id": "2e32c1e5-f8b2-491d-a885-8c165b30a060", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "bacc679d-84a2-4cce-8f42-57262b8ad1ac", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "4cabc569-28f7-404c-a250-fa1f9e4853b2", "page": 2, "type": "paragraph", "text": "3"}
{"id": "53e38272-8afe-4135-9fdb-bbadd627abad", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "918a7998-ca2e-4673-ba63-d40ab4c894d5", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "8558bcd7-0ae5-4c74-a8ac-bfc8955cf5eb", "page": 2, "type": "paragraph", "text": "Fever\u00a7"}
{"id": "4b2f0373-0d70-4570-8cb7-b632e4930172", "page": 2, "type": "paragraph", "text": "3"}
{"id": "8a57efa0-3f8e-4b60-986c-178041430065", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "9220d933-69dd-4eee-952c-ed326261a66d", "page": 2, "type": "paragraph", "text": "<1"}
{"id": "39861e46-c2b2-42ff-8bc8-4e79b58407d1", "page": 2, "type": "paragraph", "text": "2"}
{"id": "899b03a3-845c-4817-9f10-89792ea212bb", "page": 2, "type": "paragraph", "text": "0"}
{"id": "63cb3680-f811-4d5c-ad92-1ed87528be51", "page": 2, "type": "paragraph", "text": "0"}
{"id": "fbcc6d30-7f33-4540-8d3d-de68f97bdeaf", "page": 2, "type": "paragraph", "text": "NOTE: Data based on the most severe response reported by subjects. Results \u22651%"}
{"id": "8e8e55a7-7cf5-42fc-88a8-b187a8f10430", "page": 2, "type": "paragraph", "text": "reported to nearest whole percent; results >0 but <1% reported as <1%."}
{"id": "e254df06-85b3-48af-b2c9-1c76f47bb085", "page": 2, "type": "paragraph", "text": "*Total Vaccinated Cohort is de\ufb01ned as all randomized subjects who received study vaccine"}
{"id": "679a0533-b417-42b4-94c3-3f47443896d7", "page": 2, "type": "paragraph", "text": "according to the treatment actually received and who provided data."}
{"id": "894f2993-80bf-4eb4-bc47-086f7edd362a", "page": 2, "type": "paragraph", "text": "\u2020Pooled Data from Studies 3 and 4. For Studies 3 and 4, the U.S.-licensed IIV3"}
{"id": "0b7c5002-e96a-44a4-9627-6e66994a373b", "page": 2, "type": "paragraph", "text": "comparators were Fluzone and A\ufb02uria, respectively. Studies 3 and 4 are registered as"}
{"id": "1cac1f8a-5ba9-45f3-8c0a-a5b444e518bf", "page": 2, "type": "paragraph", "text": "NCT00395174 and NCT01825200, respectively, under the National Clinical Trials"}
{"id": "13a91d1a-f4d9-4b01-8427-f58a5bc3a4f2", "page": 2, "type": "paragraph", "text": "registry."}
{"id": "80f08c65-eedf-4dae-b004-6b4fa54006db", "page": 2, "type": "paragraph", "text": "\u2021Moderate = had it, and it was bad enough to prevent a signi\ufb01cant part of usual activities;"}
{"id": "75f37734-ba22-4a75-a90c-44e506948552", "page": 2, "type": "paragraph", "text": "Severe = had it, and it prevented most or all of normal activities, or had to see a doctor"}
{"id": "b72701c4-85ec-4e15-af2f-0891f8bc58e7", "page": 2, "type": "paragraph", "text": "for prescription medicine."}
{"id": "a5aebd5d-1ada-4a61-8508-3c6bd6b2d088", "page": 2, "type": "paragraph", "text": "\u00a7Fever de\ufb01ned as \u2265100.4\u00b0F (38\u00b0C). Mild (\u2265100.4\u00b0 to <101.1\u00b0F); Moderate (\u2265101.2\u00b0F to"}
{"id": "bfe8f6ae-9527-4c2b-b568-90409ca751e7", "page": 2, "type": "paragraph", "text": "<102.2\u00b0F); Severe (\u2265102.2\u00b0F)"}
{"id": "9a8009dd-04f7-4695-8423-90bfb88ae1ad", "page": 2, "type": "paragraph", "text": "2"}
{"id": "deb1ff2f-c21b-435a-91d7-d29fdbbf9b98", "page": 3, "type": "paragraph", "text": "Among adults 18-49 years of age (Studies 1 and 5 pooled), through 6 months"}
{"id": "0cea9d82-a0ad-436e-beb8-5c412b03d5c1", "page": 3, "type": "paragraph", "text": "post-vaccination, two deaths were reported, one in a Flublok recipient and one in a"}
{"id": "02832f71-d659-47ee-8e7b-661a2ca02706", "page": 3, "type": "paragraph", "text": "placebo recipient. Both deaths occurred more than 28 days following vaccination and"}
{"id": "d3dc8e56-218d-47c6-a87d-f54d39cb7f4b", "page": 3, "type": "paragraph", "text": "neither was considered vaccine-related. SAEs were reported by 32 Flublok recipients and"}
{"id": "31726f07-fbb4-4c3b-b477-5b21d94ab265", "page": 3, "type": "paragraph", "text": "35 placebo recipients. One SAE in a Flublok recipient was assessed as possibly related"}
{"id": "25e92383-ebe5-4f2c-bfc3-619372ecadcb", "page": 3, "type": "paragraph", "text": "to the vaccine: pleuropericarditis with effusions requiring hospitalization and drainage. No"}
{"id": "1fac1828-b95d-4be4-bca4-27e1097a74d7", "page": 3, "type": "paragraph", "text": "speci\ufb01c cause was identi\ufb01ed. The patient recovered."}
{"id": "fe1c8011-78c8-44de-ab5e-31d5d300a670", "page": 3, "type": "paragraph", "text": "Among adults 50-64 years of age (Studies 2 and 4 pooled), through up to 6 months or"}
{"id": "a6126933-034d-4f45-9a5e-eba951bff837", "page": 3, "type": "paragraph", "text": "30 days, post- vaccination, respectively, there were no deaths; SAEs were reported by 10"}
{"id": "e6d45ed8-14b5-414f-b790-ec00d98fcafc", "page": 3, "type": "paragraph", "text": "subjects, 6 Flublok recipients and 4 IIV3 recipients. One of the SAEs, vasovagal syncope"}
{"id": "b8c72be6-78f5-4202-9300-ec45f92de14f", "page": 3, "type": "paragraph", "text": "following injection of Flublok, was considered related to administration of study vaccine."}
{"id": "96dba0ea-34f1-4d7b-9c4c-f4950bf32949", "page": 3, "type": "paragraph", "text": "Among adults 65 years of age and older (Studies 3 and 4 pooled), through up to 6 months"}
{"id": "8e882553-e4dc-4b44-b07b-beb1c790cadc", "page": 3, "type": "paragraph", "text": "or 30 days post-vaccination, respectively, there were 4 deaths, 2 in Flublok recipients and"}
{"id": "813bfeec-28f9-42e3-a1c5-8a0af839aba6", "page": 3, "type": "paragraph", "text": "2 in IIV3 recipients. None were considered related to the study vaccines. SAEs were"}
{"id": "b3b22c88-bf55-4dda-9def-a1db542a4ae3", "page": 3, "type": "paragraph", "text": "reported from 80 subjects, 37 Flublok recipients, 43 in IIV3 recipients. No SAEs were"}
{"id": "fc772c88-4c75-4992-82a0-29a29702c614", "page": 3, "type": "paragraph", "text": "considered related to the study vaccines."}
{"id": "8e37e500-17e0-4284-a4be-e2d9b68d45eb", "page": 3, "type": "paragraph", "text": "In Study 1 (adults 18-49 years of age), the most frequent unsolicited adverse events,"}
{"id": "4c44a5af-1853-45b0-a9fc-32bb7d410bfa", "page": 3, "type": "paragraph", "text": "occurring in 1%-2% of subjects, were nasopharyngitis, upper respiratory infection,"}
{"id": "44444082-79ce-4415-a40b-aaed6ce56046", "page": 3, "type": "paragraph", "text": "headache, cough, nasal congestion, pharyngolaryngeal pain, and rhinorrhea."}
{"id": "a9a25707-f7eb-4fb2-8c84-44e52f356760", "page": 3, "type": "paragraph", "text": "Among adults 50-64 years of age (Studies 2 and 4 pooled), the most frequent unsolicited"}
{"id": "fe972f27-ff1f-4a8e-9e72-11486ba70296", "page": 3, "type": "paragraph", "text": "adverse events, occurring in 1% of subjects, were diarrhea and cough. Among adults \u226565"}
{"id": "3bc74533-297d-4fa6-a33b-9589416aeb76", "page": 3, "type": "paragraph", "text": "years of age (Studies 3 and 4 pooled), the most frequent unsolicited adverse events,"}
{"id": "cee7f058-3fc9-46dc-9eb9-0896ab720340", "page": 3, "type": "paragraph", "text": "occurring in 1% of subjects, were nasopharyngitis and cough."}
{"id": "fc5c440f-9b24-46e7-80ba-3bc121c27754", "page": 3, "type": "paragraph", "text": "Among adults 50 years of age and older (Study 4) for whom the incidence of rash,"}
{"id": "3b446787-2839-4384-a096-46a7e6898aa8", "page": 3, "type": "paragraph", "text": "urticaria, swelling, non- pitting edema, or other potential hypersensitivity reactions were"}
{"id": "34cd57f0-68e5-4a14-874f-62dd0b4e6786", "page": 3, "type": "paragraph", "text": "actively solicited for 30 days following vaccination, a total of 2.4% of Flublok recipients and"}
{"id": "c4866bdd-cf7d-4d16-8282-f2e427d1c755", "page": 3, "type": "paragraph", "text": "1.6% of IIV3 recipients reported such events over the 30 day follow-up period. A total of"}
{"id": "8187212f-a8bf-4cb9-a497-541be335065d", "page": 3, "type": "paragraph", "text": "1.9% and 0.9% of Flublok and IIV3 recipients, respectively, reported these events in the"}
{"id": "81bf84ed-be29-4292-ba1e-453f2dfcadc2", "page": 3, "type": "paragraph", "text": "7 days following vaccination. Of these solicited events, rash was most frequently reported"}
{"id": "c1383023-22d7-4307-a2a7-857a1c7e3631", "page": 3, "type": "paragraph", "text": "(Flublok 1.3%, IIV3 0.8%) over the 30 day follow-up period."}
{"id": "b08d1bfe-e081-41f0-a36f-b3dba87a2792", "page": 3, "type": "paragraph", "text": "Flublok Quadrivalent"}
{"id": "5749c53e-6c95-4666-aede-4c7761f04c2d", "page": 3, "type": "paragraph", "text": "Flublok Quadrivalent has been administered to and safety data collected from 4328 adults"}
{"id": "7188737f-7622-4f89-9eef-b068750ed964", "page": 3, "type": "paragraph", "text": "50 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72)."}
{"id": "0e8aed0d-abd7-4163-b8cb-ec15d507ffa7", "page": 3, "type": "paragraph", "text": "SAEs were collected for 6 months post-vaccination via clinic visit or remote contact."}
{"id": "8393092e-bd5e-4d59-98fe-db2f3493f7c7", "page": 3, "type": "paragraph", "text": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to"}
{"id": "7e983b4f-ff8d-471d-912f-79e2f273976e", "page": 3, "type": "paragraph", "text": "receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by"}
{"id": "d812e114-0501-46a6-97ba-59eb07f0c120", "page": 3, "type": "paragraph", "text": "GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis"}
{"id": "194d3fab-4883-43d7-9c4a-4bacaade9cc8", "page": 3, "type": "paragraph", "text": "population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine"}
{"id": "4aea63ef-02a1-4a01-b75b-31cf03bb92f7", "page": 3, "type": "paragraph", "text": "recipients. The mean age of participants was 62.7 years. Overall, 58% of subjects were"}
{"id": "4c39f3bc-2f6d-499b-a50c-5f2fbcaf3c0e", "page": 3, "type": "paragraph", "text": "female, 80% white/Caucasian, 18% black/African American, 0.9% American Indian/"}
{"id": "e7edc65a-3292-410f-9c70-5bc16b811e42", "page": 3, "type": "paragraph", "text": "Alaskan Native, 0.4% Asian, 0.2% Native Hawaiian/Paci\ufb01c Islander, 0.7% other racial"}
{"id": "19bfae02-ac39-417c-a5ae-c1dfab570e5c", "page": 3, "type": "paragraph", "text": "groups, and 5% of Hispanic/Latino ethnicity."}
{"id": "ddd39ef6-39da-4a2c-9f08-dbd9532b646e", "page": 3, "type": "paragraph", "text": "Among adults 50 years of age and older (Study 6), there were no SAEs considered related"}
{"id": "241eb94d-715e-4c2d-8e76-76d7a7992905", "page": 3, "type": "paragraph", "text": "to study vaccine."}
{"id": "9db625be-a81b-4576-a2d4-5d804b05c0b3", "page": 3, "type": "paragraph", "text": "Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to"}
{"id": "f4a5ffc9-a9bb-4998-af0b-113fb87785d8", "page": 3, "type": "paragraph", "text": "receive Flublok Quadrivalent or a Comparator inactivated in\ufb02uenza vaccine (Fluarix\u00ae"}
{"id": "0e7e416a-ac79-4a2d-9337-e4d93be9fad0", "page": 3, "type": "paragraph", "text": "Quadrivalent, manufactured by GlaxoSmithKline). The safety analysis population included"}
{"id": "d5a94b40-b004-44ad-b26b-7cfab6b044f8", "page": 3, "type": "paragraph", "text": "998 recipients of Flublok Quadrivalent and 332 Comparator vaccine recipients. The mean"}
{"id": "263616e5-f23b-420f-ad2f-b2d748974391", "page": 3, "type": "paragraph", "text": "age of participants was 33.5 years. Overall, 65% of subjects were female, 59%"}
{"id": "806a54f4-b3ca-4c33-9261-48962e89b341", "page": 3, "type": "paragraph", "text": "white/Caucasian, 37% black/African American, 1.0% Native Hawaiian/Paci\ufb01c Islander,"}
{"id": "1b422f20-322c-4800-93fd-7cf27e01089e", "page": 3, "type": "paragraph", "text": "0.8% American Indian/Alaskan Native, 0.5% Asian, 1.4% other racial groups, and 16% of"}
{"id": "907b9f2f-3ba8-4dd7-803b-ef8e23c15898", "page": 3, "type": "paragraph", "text": "Hispanic/Latino ethnicity."}
{"id": "d782a84d-4f1c-45e5-9b02-8358df3393b7", "page": 3, "type": "paragraph", "text": "Among adults 18-49 years of age (Study 7), through 6 months post-vaccination, there were"}
{"id": "dc3f2750-01b5-454c-a2cb-9431629effc5", "page": 3, "type": "paragraph", "text": "no SAEs considered related to study vaccine."}
{"id": "d239de06-c901-4a78-82ed-0fdd0b6aabbc", "page": 3, "type": "paragraph", "text": "1NCT02285998"}
{"id": "5add8f4c-db6c-4ab9-9e43-99f6017b58c4", "page": 3, "type": "paragraph", "text": "2NCT02290509"}
{"id": "a8dbf92d-d5e8-4be1-9b12-198bef6ed7c4", "page": 3, "type": "paragraph", "text": "6.2"}
{"id": "7523ef88-6db8-45e3-955a-acc482d8a2d0", "page": 3, "type": "paragraph", "text": "Postmarketing Experience"}
{"id": "c31d056a-5989-4138-ae10-74b3874036eb", "page": 3, "type": "paragraph", "text": "The following events have been spontaneously reported during post approval use of"}
{"id": "4ba30658-1a93-45fd-ba0f-d3c84f993656", "page": 3, "type": "paragraph", "text": "Flublok or Flublok Quadrivalent. They are described because of the temporal relationship,"}
{"id": "28bc5bf0-cf92-4de8-9412-b11c2891d17b", "page": 3, "type": "paragraph", "text": "the biologic plausibility for a causal relationship to Flublok or Flublok Quadrivalent, and"}
{"id": "82f71e8f-9418-4b9f-b0b0-62e0d2a17d82", "page": 3, "type": "paragraph", "text": "their potential seriousness. Because these events are reported voluntarily from a"}
{"id": "b234167a-bb88-42b1-a044-e130ce7be0b7", "page": 3, "type": "paragraph", "text": "population of uncertain size, it is not always possible to reliably estimate their frequency"}
{"id": "0470ad7e-329d-4b97-a2b3-577e20d8d81d", "page": 3, "type": "paragraph", "text": "or establish a causal relationship to vaccine exposure."}
{"id": "2da1fe85-9d24-4737-86fe-24213aaa68c4", "page": 3, "type": "paragraph", "text": "Immune system disorders: anaphylaxis, allergic reactions, and other forms of hypersen-"}
{"id": "4a7491f2-4050-4705-a306-72124a75fbad", "page": 3, "type": "paragraph", "text": "sitivity (including urticaria)."}
{"id": "e24f0939-2147-40fd-be3f-80059fc2a62e", "page": 3, "type": "paragraph", "text": "Nervous system disorders: facial palsy (Bell\u2019s palsy), Guillain-Barr\u00e9 syndrome, syncope."}
{"id": "6af8719a-8e56-4a2b-b387-9eea6c9d46a4", "page": 3, "type": "paragraph", "text": "8"}
{"id": "0eb29ab4-761b-4287-8ad6-de6ae227f08e", "page": 3, "type": "paragraph", "text": "USE IN SPECIFIC POPULATIONS"}
{"id": "3be017d7-7b36-43ca-a454-b002b48a4aed", "page": 3, "type": "paragraph", "text": "8.1"}
{"id": "b5b55c16-6a93-4120-aad0-72fc32b058a2", "page": 3, "type": "paragraph", "text": "Pregnancy"}
{"id": "cc17f835-0d05-42f3-ae42-b493a310973e", "page": 3, "type": "paragraph", "text": "Pregnancy Exposure"}
{"id": "bce2c4fc-ab73-4e4c-b410-87e428d20951", "page": 3, "type": "paragraph", "text": "There is a pregnancy exposure registry that monitors pregnancy outcomes in women"}
{"id": "6c2eeb78-1660-4cf6-b62f-8207443b1b3c", "page": 3, "type": "paragraph", "text": "exposed to Flublok."}
{"id": "dc24c1b9-06e7-4753-a597-a56ded0143ec", "page": 3, "type": "paragraph", "text": "Healthcare providers are encouraged to enroll women who receive Flublok during"}
{"id": "19f00743-af6e-43f2-bbbb-2aa824d6aa24", "page": 3, "type": "paragraph", "text": "pregnancy in Sano\ufb01Pasteur Inc.\u2019s vaccination pregnancy registry by calling 1-800-822-"}
{"id": "a22ae2ba-1155-4b93-90f9-64d820446882", "page": 3, "type": "paragraph", "text": "2463."}
{"id": "913dabc4-07b9-4641-87a9-57b5397a3264", "page": 3, "type": "paragraph", "text": "Risk Summary"}
{"id": "53b0c9e8-c6a3-4f5a-9489-6e73e283ed1d", "page": 3, "type": "paragraph", "text": "All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S."}
{"id": "8fb37cc1-dfd0-410e-ba87-f4f5f9798cfa", "page": 3, "type": "paragraph", "text": "general population, the estimated background risks of major birth defects and miscarriage"}
{"id": "4d896550-9477-4fcd-b58a-e5e789bd02b5", "page": 3, "type": "paragraph", "text": "in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. Available"}
{"id": "52c767f3-42b8-4966-ad70-1a1ac65afa32", "page": 3, "type": "paragraph", "text": "data on Flublok and Flublok Quadrivalent administered to pregnant women are limited and"}
{"id": "d33dc188-7be1-45fd-8ba0-575799ed5b5d", "page": 3, "type": "paragraph", "text": "insufficient to inform vaccine-associated risks in pregnant women."}
{"id": "5fe02fc2-aef0-4c78-a45f-ba7213b0dce9", "page": 3, "type": "paragraph", "text": "A developmental study of Flublok has been performed in rats administered 0.5 mL"}
{"id": "2620677c-7cb1-4bf2-a9ec-2596bd36e188", "page": 3, "type": "paragraph", "text": "(divided, a single human dose is 0.5 mL) of Flublok prior to mating and during gestation."}
{"id": "9d067fdf-372b-4a1c-b199-0d9f0f032ab5", "page": 3, "type": "paragraph", "text": "This study revealed no evidence of harm to the fetus due to Flublok (see Data)."}
{"id": "ca381b8f-0b3b-4728-8b99-fba89521e66f", "page": 3, "type": "paragraph", "text": "Clinical Considerations"}
{"id": "78f9ec7a-1d8d-4494-b541-74b0ec9ebb2b", "page": 3, "type": "paragraph", "text": "Disease-associated Maternal and/or Embryo/Fetal Risk"}
{"id": "35a406c5-4ac4-43d6-ae66-7c892740e715", "page": 3, "type": "paragraph", "text": "Pregnant women are at increased risk of complications associated with in\ufb02uenza infection"}
{"id": "4e88d504-12aa-4938-b49a-2a3aa560ec77", "page": 3, "type": "paragraph", "text": "compared to non-pregnant women. Pregnant women with in\ufb02uenza may be at increased"}
{"id": "15c815ea-d720-467d-a10e-681579d67b84", "page": 3, "type": "paragraph", "text": "risk for adverse pregnancy outcomes, including preterm labor and delivery."}
{"id": "ddfcedca-5ae7-438a-91f5-036db7462a77", "page": 3, "type": "paragraph", "text": "Data"}
{"id": "6fa110b4-5027-4325-9e4b-001c4240a5af", "page": 3, "type": "paragraph", "text": "Animal"}
{"id": "de97afb5-bbd7-4b5d-a156-96b09326ed35", "page": 3, "type": "paragraph", "text": "In a developmental toxicity study, female rats were administered Flublok by intramuscular"}
{"id": "195548c6-397e-4154-8899-0f334d1d4921", "page": 3, "type": "paragraph", "text": "injection twice prior to mating (35 days and 14 days prior to mating) and on gestation Day"}
{"id": "3e761d5c-d811-48d7-b7fa-8ef445e25157", "page": 3, "type": "paragraph", "text": "6. The total dose was 0.5 mL (divided) on each occasion (a human dose is 0.5 mL). No"}
{"id": "8437867a-0e35-4897-af98-7de1a6a668eb", "page": 3, "type": "paragraph", "text": "vaccine-related fetal malformations or variations and no adverse effects on pre-weaning"}
{"id": "9a435d00-ca17-4d22-ae70-cd2aef556b29", "page": 3, "type": "paragraph", "text": "development or female fertility were observed in the study."}
{"id": "e7f11582-df4f-4572-856a-83dca0227725", "page": 3, "type": "paragraph", "text": "8.2"}
{"id": "a805aae9-48f7-4b6f-b34f-512fab2bdbcc", "page": 3, "type": "paragraph", "text": "Lactation"}
{"id": "c1aa697c-cc9a-4d34-86ee-e86bba6d2a29", "page": 3, "type": "paragraph", "text": "Risk Summary"}
{"id": "cfa26ff5-8e77-4fe8-a6bb-3742a3f7bc3a", "page": 3, "type": "paragraph", "text": "It is not known whether Flublok is excreted in human milk. Data are not available to assess"}
{"id": "e5ec3f4b-59e1-4046-89a3-5550291b62fe", "page": 3, "type": "paragraph", "text": "the effects of Flublok on the breastfed infant or on milk production/excretion."}
{"id": "46bdfcfa-4899-44a7-8f7a-a391bfae4c9d", "page": 3, "type": "paragraph", "text": "The developmental and health bene\ufb01ts of breastfeeding should be considered along with"}
{"id": "bc71a82b-7b77-4495-97b8-cb8311f4c945", "page": 3, "type": "paragraph", "text": "the mother\u2019s clinical need for Flublok and any potential adverse effects on the breastfed"}
{"id": "76448f42-d18e-414e-ba06-ac8c574b295c", "page": 3, "type": "paragraph", "text": "child from Flublok or from the underlying maternal condition. For preventive vaccines, the"}
{"id": "ce3fec66-825d-4ee5-85f2-2d70fbe37f0a", "page": 3, "type": "paragraph", "text": "underlying condition is susceptibility to disease prevented by the vaccine."}
{"id": "4fb41b99-db43-4515-aef6-6fba7da3171d", "page": 3, "type": "paragraph", "text": "8.4"}
{"id": "8534fcf3-f502-4d17-802e-113c65333c6f", "page": 3, "type": "paragraph", "text": "Pediatric Use"}
{"id": "5bdc783f-7b7f-4e31-a916-25d2a4bb6f79", "page": 3, "type": "paragraph", "text": "Data from a randomized, controlled trial demonstrated that children 6 months to less than"}
{"id": "ea9f219a-ef63-4fd8-b7b1-f9412927de68", "page": 3, "type": "paragraph", "text": "3 years of age had diminished hemagglutinin inhibition (HI) responses to Flublok"}
{"id": "f826388b-89ec-4ab0-aa37-09ab7a73ec4a", "page": 3, "type": "paragraph", "text": "compared to a U.S.-licensed in\ufb02uenza vaccine approved for use in this population, strongly"}
{"id": "65784c93-22c4-4a1c-81f0-9d6d4e15223a", "page": 3, "type": "paragraph", "text": "suggesting that Flublok would not be effective in children younger than 3 years of age (6)."}
{"id": "ab1d735c-b3e9-43c9-9231-2e26ac9fe089", "page": 3, "type": "paragraph", "text": "Safety and effectiveness of Flublok have not been established in children 3 years to less"}
{"id": "f4885280-c1fc-4d23-8e78-d07045dcd31b", "page": 3, "type": "paragraph", "text": "than 18 years of age."}
{"id": "e81b180c-d278-4f37-a434-2b8e7508aedd", "page": 3, "type": "paragraph", "text": "8.5"}
{"id": "5ec5aed8-4733-41b0-997b-dc8725826c34", "page": 3, "type": "paragraph", "text": "Geriatric Use"}
{"id": "c0939986-5fad-4461-b5c5-6ee8d0e5a57e", "page": 3, "type": "paragraph", "text": "Data from an efficacy study (Study 6), which included 1759 subjects \u226565 years and 525"}
{"id": "8f7a1fad-f6a2-4646-b6d7-87e80a219879", "page": 3, "type": "paragraph", "text": "subjects \u226575 years who received Flublok Quadrivalent, are insufficient to determine"}
{"id": "24e3fba6-cabc-4124-a98a-0b45d46f13db", "page": 3, "type": "paragraph", "text": "whether elderly subjects respond differently from younger subjects (See Clinical Studies"}
{"id": "c1240916-8dd2-4d7e-b346-88c98ca218cc", "page": 3, "type": "paragraph", "text": "[14]). Data for Flublok Quadrivalent are relevant to Flublok because both vaccines are"}
{"id": "0f4fa916-cc97-4793-917a-a1f6cbe0cc88", "page": 3, "type": "paragraph", "text": "manufactured using the same process and have overlapping compositions."}
{"id": "3ca538c8-230c-43dc-a8bd-19f1cb644234", "page": 3, "type": "paragraph", "text": "11"}
{"id": "69a7b05d-6ed1-4d5e-bf30-c6ee7e8a5d1f", "page": 3, "type": "paragraph", "text": "DESCRIPTION"}
{"id": "432a2e6e-adc5-45f4-a19d-683c500f6616", "page": 3, "type": "paragraph", "text": "Flublok [In\ufb02uenza Vaccine] is a sterile, clear, colorless injection containing recombinant"}
{"id": "b0fddf3a-63a2-4407-af41-1254c2fdf797", "page": 3, "type": "paragraph", "text": "hemagglutinin (HA) proteins from three in\ufb02uenza viruses for intramuscular use. It contains"}
{"id": "ca43a2f7-3ebd-46a8-b246-2d420925b88c", "page": 3, "type": "paragraph", "text": "puri\ufb01ed HA proteins produced in a continuous insect cell line (expresSF+\u00ae) that is derived"}
{"id": "bf6cb5e2-1d76-4ae2-b29b-1046d19a91c4", "page": 3, "type": "paragraph", "text": "from Sf9 cells of the fall armyworm, Spodoptera frugiperda (which is related to moths,"}
{"id": "96084a9d-a58f-4327-a76e-504488946ca2", "page": 3, "type": "paragraph", "text": "caterpillars and butter\ufb02ies), and grown in serum-free medium composed of chemically-"}
{"id": "795e4678-3d9c-4024-a38c-371e0bdbb258", "page": 3, "type": "paragraph", "text": "de\ufb01ned lipids, vitamins, amino acids, and mineral salts. Each of the three HAs is"}
{"id": "ba20a280-132e-476e-8385-6b7439c56b5f", "page": 3, "type": "paragraph", "text": "expressed in this cell line using a baculovirus vector (Autographa californica nuclear"}
{"id": "1a72a28f-ac35-4619-80f9-b3ca6d6b026a", "page": 3, "type": "paragraph", "text": "polyhedrosis virus), extracted from the cells with Triton X-100 and further puri\ufb01ed by"}
{"id": "916b2d48-799e-4197-823f-4aaae4d8c887", "page": 3, "type": "paragraph", "text": "column chromatography. The puri\ufb01ed HAs are then blended and \ufb01lled into single-dose"}
{"id": "cdbdab83-78ea-44e9-8ecd-a55172593153", "page": 3, "type": "paragraph", "text": "syringes."}
{"id": "6d57146b-ce62-460a-b74c-00470b83f473", "page": 3, "type": "paragraph", "text": "Flublok is standardized according to United States Public Health Service (USPHS)"}
{"id": "b1b5fd8a-0d63-4fec-8fff-d6b4ebb6a940", "page": 3, "type": "paragraph", "text": "requirements. For the 2024-2025 in\ufb02uenza season it is formulated to contain 135 mcg HA"}
{"id": "eab4a149-c0ae-43ca-b040-f87b5e4d3073", "page": 3, "type": "paragraph", "text": "per 0.5 mL dose, with 45 mcg HA of each of the following 3 in\ufb02uenza virus strains: A/West"}
{"id": "8b7675dc-331d-47eb-8d8a-87723f446f6e", "page": 3, "type": "paragraph", "text": "Virginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/"}
{"id": "6ece2c1b-4145-46f3-b53f-489594c9630e", "page": 3, "type": "paragraph", "text": "2022 (H3N2) and B/Austria/1359417/2021."}
{"id": "da5fb769-780f-4e68-876b-314a60fc5efb", "page": 3, "type": "paragraph", "text": "A single 0.5 mL dose of Flublok contains sodium chloride (4.4 mg), monobasic sodium"}
{"id": "10573d92-d04f-4c8e-8fa8-5c60a3ede0eb", "page": 3, "type": "paragraph", "text": "phosphate (0.2 mg), dibasic sodium phosphate (0.5 mg), and polysorbate 20 (Tween\u00ae20)"}
{"id": "28dcde2d-fc70-4a69-a12d-a25bee4f04a2", "page": 3, "type": "paragraph", "text": "(27.5 mcg). Each 0.5 mL dose of Flublok may also contain residual amounts of baculovirus"}
{"id": "14049aee-973c-4876-845f-120cb89ddb9a", "page": 3, "type": "paragraph", "text": "and Spodoptera frugiperda cell proteins (\u226414.3 mcg), baculovirus and cellular DNA (\u226410"}
{"id": "a42f14cf-7ffc-4c5e-94bf-0b2317cf7f9b", "page": 3, "type": "paragraph", "text": "ng), and Triton X-100 (\u2264100 mcg)."}
{"id": "661090e5-8df6-4845-bbaf-36aacef688b9", "page": 3, "type": "paragraph", "text": "Flublok contains no egg proteins, antibiotics, or preservatives. The single-dose, pre\ufb01lled"}
{"id": "32c7873c-0d57-4227-9f59-f899c2da1400", "page": 3, "type": "paragraph", "text": "syringes contain no natural rubber latex."}
{"id": "52aee696-550d-4685-9f5a-5fab5459c085", "page": 3, "type": "paragraph", "text": "12"}
{"id": "4b37a833-218b-4ea7-8460-18a24dd9bba0", "page": 3, "type": "paragraph", "text": "CLINICAL PHARMACOLOGY"}
{"id": "3d3a0a92-7389-459d-8027-0569ce2ac705", "page": 3, "type": "paragraph", "text": "12.1 Mechanism of Action"}
{"id": "0bf72641-60b5-4ad0-a07a-0599cf2e6988", "page": 3, "type": "paragraph", "text": "Flublok contains recombinant HA proteins of the three strains of in\ufb02uenza virus speci\ufb01ed"}
{"id": "5d31ef9e-288b-495f-b42b-cf07426481a9", "page": 3, "type": "paragraph", "text": "by health authorities for inclusion in the annual seasonal vaccine. These proteins function"}
{"id": "abda5785-428d-4f6b-9cee-06746ae64c82", "page": 3, "type": "paragraph", "text": "as antigens which induce a humoral immune response, measured by hemagglutination"}
{"id": "77ba619b-3f26-4d6d-8e9f-a598335aca9f", "page": 3, "type": "paragraph", "text": "inhibition (HI) antibody)."}
{"id": "e9d35737-0daf-4aec-8b9c-41b08af42521", "page": 3, "type": "paragraph", "text": "Antibodies against one in\ufb02uenza virus type or subtype confer limited or no protection"}
{"id": "04cf95c3-9dc6-4eab-915a-0a218287c841", "page": 3, "type": "paragraph", "text": "against another. Furthermore, antibodies to one antigenic variant of in\ufb02uenza virus might"}
{"id": "6d6e5363-a61c-45ca-880c-98b840d14cdf", "page": 3, "type": "paragraph", "text": "not protect against a new antigenic variant of the same type or subtype. Frequent"}
{"id": "0806de40-af63-4793-8e30-c591e8bca5ad", "page": 3, "type": "paragraph", "text": "development of antigenic variants through antigenic drift is the virologic basis for seasonal"}
{"id": "2af793e0-4f3e-4bc1-9dc6-a565b8290baf", "page": 3, "type": "paragraph", "text": "epidemics and the reason for the usual replacement of one or more in\ufb02uenza virus strains"}
{"id": "7633398d-ca66-4842-9790-ca9ae0068165", "page": 3, "type": "paragraph", "text": "in each year\u2019s in\ufb02uenza vaccine."}
{"id": "300689f3-2972-4f30-8f69-ce61da69e9b1", "page": 3, "type": "paragraph", "text": "13"}
{"id": "08478599-fce5-4456-9c2d-d88631ff106f", "page": 3, "type": "paragraph", "text": "NONCLINICAL TOXICOLOGY"}
{"id": "eb0286c6-7f61-4a0f-bc9b-0bdfd5a867f7", "page": 3, "type": "paragraph", "text": "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility"}
{"id": "5c430a21-6a7d-4b79-a1ee-4c970d4add2e", "page": 3, "type": "paragraph", "text": "Flublok has not been evaluated for carcinogenic or mutagenic potential, or for impairment"}
{"id": "3ba5dfa8-54b4-4f6a-8670-023d18bdb9a7", "page": 3, "type": "paragraph", "text": "of male fertility in animals."}
{"id": "f7058d7d-b0b5-42dd-a3b9-0585805cc7b8", "page": 3, "type": "paragraph", "text": "14"}
{"id": "f5d6dd21-51f3-429e-b4e4-4d9c778dd8c3", "page": 3, "type": "paragraph", "text": "CLINICAL STUDIES"}
{"id": "3e34d68b-d412-43ae-b37b-01e2da33b32a", "page": 3, "type": "paragraph", "text": "14.1 Efficacy Against Laboratory-Con\ufb01rmed In\ufb02uenza"}
{"id": "621e98be-953b-4e4a-8d8f-cffc747ba2a6", "page": 3, "type": "paragraph", "text": "The efficacy of Flublok in protecting against culture-con\ufb01rmed in\ufb02uenza illness was"}
{"id": "d4ede766-e007-494d-b807-5aa4b63c59b8", "page": 3, "type": "paragraph", "text": "evaluated in a randomized, observer-blind, placebo-controlled multicenter trial conducted"}
{"id": "42fc751e-821e-490b-9664-ea73855bc749", "page": 3, "type": "paragraph", "text": "in the U.S. during the 2007-2008 in\ufb02uenza season in adults 18-49 years of age (Study"}
{"id": "d8286335-adb5-441c-b4cd-a1371baf3e24", "page": 3, "type": "paragraph", "text": "1). (1)"}
{"id": "76bc1d47-5b5a-4500-89b9-8fa7099abaec", "page": 3, "type": "paragraph", "text": "Study 1 enrolled and vaccinated 4648 healthy adults (mean age 32.5 years) randomized"}
{"id": "79d31d9d-8fe0-4600-bdd6-b5a4364508c8", "page": 3, "type": "paragraph", "text": "in a 1:1 ratio to receive a single dose of Flublok (n=2344) or saline placebo (n=2304)."}
{"id": "5dafa696-9b5f-4679-9e19-38e935e2e0eb", "page": 3, "type": "paragraph", "text": "Among enrolled subjects, 59% were female, 67% were white, 19% African-American, 2%"}
{"id": "be4fe0ab-e3ac-4d1b-9fb4-044a3b593052", "page": 3, "type": "paragraph", "text": "Asian, < 1% other races, and 11% of Latino/Hispanic ethnicity. Culture-con\ufb01rmed in\ufb02uenza"}
{"id": "3d098d86-a69a-4469-9925-18a4ac04b353", "page": 3, "type": "paragraph", "text": "was assessed by active and passive surveillance for in\ufb02uenza-like illness (ILI) beginning"}
{"id": "1d3a241b-324b-443e-8d29-c3869efbad4a", "page": 3, "type": "paragraph", "text": "2 weeks post-vaccination until the end of the in\ufb02uenza season, approximately 7 months"}
{"id": "d119f09f-5e2a-4d5e-9305-7d7e024cfede", "page": 3, "type": "paragraph", "text": "post- vaccination. ILI was de\ufb01ned as having at least 2 of 3 symptoms (no speci\ufb01ed"}
{"id": "a6cf3b10-98e8-4a25-967f-5f671838a065", "page": 3, "type": "paragraph", "text": "duration) in the following categories: 1) fever \u2265100\u00b0F; 2) respiratory symptoms (cough,"}
{"id": "50756658-2af9-44be-9d9c-a94c2bb2e721", "page": 3, "type": "paragraph", "text": "sore throat, or runny nose/stuffy nose); or 3) systemic symptoms (myalgias, arthralgias,"}
{"id": "45c4a4f6-fb65-404d-bddb-367d7fd5e284", "page": 3, "type": "paragraph", "text": "headache, chills/sweats, or tiredness/malaise). For subjects with an episode of ILI, nasal"}
{"id": "7e492e2a-4850-47cf-b3de-366061e49aab", "page": 3, "type": "paragraph", "text": "and throat swab samples were collected for viral culture."}
{"id": "28fc9e76-a99a-4c1b-a6f2-1391f19e7fb3", "page": 3, "type": "paragraph", "text": "3"}
{"id": "9b726450-7820-420b-9e6d-333a6e7c329c", "page": 4, "type": "paragraph", "text": "The primary efficacy endpoint of Study 1 was Centers for Disease Control-de\ufb01ned"}
{"id": "44e42978-8539-4b8f-8cde-db8e42b55bfe", "page": 4, "type": "paragraph", "text": "in\ufb02uenza-like illness (CDC-ILI) with a positive culture for an in\ufb02uenza virus strain"}
{"id": "412aafa1-0a96-4934-bd34-ba77f0e38f45", "page": 4, "type": "paragraph", "text": "antigenically resembling a strain represented in Flublok. CDC-ILI is de\ufb01ned as fever of"}
{"id": "0a71e4e1-6d7b-4829-aa3e-43831c75461f", "page": 4, "type": "paragraph", "text": "\u2265100\u00b0F oral accompanied by cough, sore throat, or both on the same day or on"}
{"id": "1cd54424-c538-41d4-b95a-b9de4c1fe3e3", "page": 4, "type": "paragraph", "text": "consecutive days. Attack rates and vaccine efficacy (VE), de\ufb01ned as the reduction in the"}
{"id": "5d9ce0ac-b665-4237-a29d-f18d7ca9c533", "page": 4, "type": "paragraph", "text": "in\ufb02uenza rate for Flublok relative to placebo, were calculated for the total vaccinated cohort"}
{"id": "2390d1ab-f80d-4803-b5b2-eded6e862ed5", "page": 4, "type": "paragraph", "text": "(n=4648)."}
{"id": "f050293b-de64-4354-9e06-7878940c6709", "page": 4, "type": "paragraph", "text": "The pre-de\ufb01ned success criterion for the primary efficacy analysis was that the lower"}
{"id": "a97bb0f4-9896-4b2f-b91d-e1749018107e", "page": 4, "type": "paragraph", "text": "bound of the 95% con\ufb01dence interval (CI) of VE should be at least 40%. Vaccine efficacy"}
{"id": "596835e7-25e0-403b-8669-52540b5cc30e", "page": 4, "type": "paragraph", "text": "against antigenically matched culture-con\ufb01rmed CDC-ILI could not be determined reliably"}
{"id": "b26cae6d-661a-4ce4-bf7f-aa33b7b38bc2", "page": 4, "type": "paragraph", "text": "because 96% of the in\ufb02uenza isolates obtained from subjects in Study 1 were not"}
{"id": "5406d290-02d2-4118-8698-70e44dfc0d52", "page": 4, "type": "paragraph", "text": "antigenically matched to the strains represented in the vaccine. An exploratory analysis"}
{"id": "6b587bd8-57ba-4cfb-837a-a1aec5357dd4", "page": 4, "type": "paragraph", "text": "of VE of Flublok against all strains, regardless of antigenic match, isolated from any"}
{"id": "9e9fd143-00f5-404e-b6d2-c3f09f00b497", "page": 4, "type": "paragraph", "text": "subject with an ILI, not necessarily meeting CDC- ILI criteria, demonstrated an efficacy"}
{"id": "06d7c5a1-0cf4-4715-8665-b4bcd316dd8d", "page": 4, "type": "paragraph", "text": "estimate of 44.8% (95% CI 24.4, 60.0). See Table 4 for a presentation of VE by case"}
{"id": "3c5ef3b1-2159-430e-a93f-54d2e262fd7e", "page": 4, "type": "paragraph", "text": "de\ufb01nition and antigenic similarity."}
{"id": "7ea89e3a-de84-459e-be25-c41ad0cf98fa", "page": 4, "type": "paragraph", "text": "Table 4: Vaccine Efficacy Against Culture-Con\ufb01rmed In\ufb02uenza in Healthy"}
{"id": "5461d8db-7169-4548-8eec-50009b7cfc2e", "page": 4, "type": "paragraph", "text": "Adults 18-49 Years of Age, Study 1*"}
{"id": "54950b9c-954d-4f40-b218-6787ebdc339a", "page": 4, "type": "paragraph", "text": "Case de\ufb01nition"}
{"id": "0a02a554-b300-46de-8be7-54399de3604c", "page": 4, "type": "paragraph", "text": "Flublok"}
{"id": "066563e9-4650-452c-89e2-33b4e92b0417", "page": 4, "type": "paragraph", "text": "(N=2344)"}
{"id": "6a57e4ba-66c5-424e-991e-7a54e92923c6", "page": 4, "type": "paragraph", "text": "Saline"}
{"id": "67e0d2df-370a-4715-9099-3f6b554833f5", "page": 4, "type": "paragraph", "text": "Placebo"}
{"id": "4e98563a-53ce-42e4-8876-38282013a9f6", "page": 4, "type": "paragraph", "text": "(N=2304)"}
{"id": "520d2128-e7e2-4579-8cb0-4db9bb755064", "page": 4, "type": "paragraph", "text": "Flublok"}
{"id": "5fbbba7d-96d3-4a1f-b581-ae07ac9bf974", "page": 4, "type": "paragraph", "text": "Vaccine"}
{"id": "53db7096-8ca4-40df-a958-f862f8522771", "page": 4, "type": "paragraph", "text": "Efficacy\u2020,"}
{"id": "792693ce-7f1b-4b21-a25e-b84fbe117baf", "page": 4, "type": "paragraph", "text": "%"}
{"id": "f3adf986-f82e-4c08-8971-f2054122e99b", "page": 4, "type": "paragraph", "text": "95%"}
{"id": "cbfa80b7-5b27-4187-aae1-e30df12363ac", "page": 4, "type": "paragraph", "text": "Con\ufb01dence"}
{"id": "21999b77-05f2-438a-9f50-d0ce39ee89e4", "page": 4, "type": "paragraph", "text": "Interval"}
{"id": "95d70a82-8b0d-439a-9e01-e01ca2ec4417", "page": 4, "type": "paragraph", "text": "Cases,"}
{"id": "8bedc8d4-a873-44cf-bbef-202c1da5dcb1", "page": 4, "type": "paragraph", "text": "n"}
{"id": "55315d65-1255-4491-b2c2-ef9999cd1998", "page": 4, "type": "paragraph", "text": "Rate,"}
{"id": "434d30ac-1c92-4c16-adff-d371cbc4dd8d", "page": 4, "type": "paragraph", "text": "%"}
{"id": "69da65b1-20f0-40dd-845c-52d859d2584e", "page": 4, "type": "paragraph", "text": "Cases,"}
{"id": "d80dcbd1-9759-4664-80f0-79507efb4a24", "page": 4, "type": "paragraph", "text": "n"}
{"id": "434923d3-7caf-4e8d-9da7-c13054a30738", "page": 4, "type": "paragraph", "text": "Rate,"}
{"id": "a06682b6-734d-4bcb-b435-278fef6ff2a1", "page": 4, "type": "paragraph", "text": "%"}
{"id": "c2f232e4-46dd-4b43-844e-b302f23e9b1f", "page": 4, "type": "paragraph", "text": "Positive culture with a strain represented in the vaccine"}
{"id": "470d86ee-ee46-4ba1-9fc6-a23b34dc996c", "page": 4, "type": "paragraph", "text": "CDC-ILI, all"}
{"id": "a7c42269-2e99-452e-8bac-943898a1a4b5", "page": 4, "type": "paragraph", "text": "matched strains\u2021,\u00a7"}
{"id": "a2a256c5-fb2b-4f2b-9c3b-aa975843fa6d", "page": 4, "type": "paragraph", "text": "1"}
{"id": "2b5666c3-ec58-4ab0-9d3b-1054739a9a76", "page": 4, "type": "paragraph", "text": "0.04"}
{"id": "809f5977-0d27-48f6-a765-7e9f592ff9c4", "page": 4, "type": "paragraph", "text": "4"}
{"id": "ef70b316-023c-480a-9859-e4bbc3c64c06", "page": 4, "type": "paragraph", "text": "0.2"}
{"id": "d2f91fbd-fa00-4e31-8697-93d952d43710", "page": 4, "type": "paragraph", "text": "75.4"}
{"id": "0fb95d92-c6a9-46a7-80af-317fda9ddb62", "page": 4, "type": "paragraph", "text": "(-148.0,"}
{"id": "56a0add0-7e1d-403e-a40b-9a42e86feda5", "page": 4, "type": "paragraph", "text": "99.5)"}
{"id": "5484da90-4f8d-4b53-923e-093a2f0e2361", "page": 4, "type": "paragraph", "text": "Any ILI, all"}
{"id": "e9611e67-2b69-4605-a75f-62a0bc6d8a35", "page": 4, "type": "paragraph", "text": "matched strains\u00b6,#"}
{"id": "f8af0ba4-523e-42fd-afa8-5ebc784c973e", "page": 4, "type": "paragraph", "text": "2"}
{"id": "2ce20709-89fd-4ac7-bbdd-85d0c176da85", "page": 4, "type": "paragraph", "text": "0.1"}
{"id": "5ccaf372-a4aa-4c11-ac10-cd57dbf3e528", "page": 4, "type": "paragraph", "text": "6"}
{"id": "9218eff3-5f1d-49f8-badf-61dd9bd259f0", "page": 4, "type": "paragraph", "text": "0.3"}
{"id": "b6a8b679-2acc-405e-ab43-fdb771b29461", "page": 4, "type": "paragraph", "text": "67.2"}
{"id": "a925af5a-cd7e-4e0e-9d25-95a2c0173239", "page": 4, "type": "paragraph", "text": "(-83.2,"}
{"id": "9d7c60ae-8922-40ac-b1da-7b44dda80ed3", "page": 4, "type": "paragraph", "text": "96.8)"}
{"id": "9f8a78c8-375b-412e-b490-a222cbae38bf", "page": 4, "type": "paragraph", "text": "Positive culture with any strain, regardless of match to the vaccine"}
{"id": "797d9ab9-7698-46ef-955a-b71bd4ee3f55", "page": 4, "type": "paragraph", "text": "CDC-ILI, all"}
{"id": "9b6a2f45-8c7c-437d-b7ac-ea68ff9df1ba", "page": 4, "type": "paragraph", "text": "strains\u2021,\u00de"}
{"id": "1e6cdeff-4604-4309-b796-34bfab306e73", "page": 4, "type": "paragraph", "text": "44"}
{"id": "0def6f6c-d728-4b2f-86b3-90cba4665106", "page": 4, "type": "paragraph", "text": "1.9"}
{"id": "aa96aa42-3550-42ee-b459-07164a7a24dd", "page": 4, "type": "paragraph", "text": "78"}
{"id": "af21a8f6-63e5-4588-8e42-9536b324ab37", "page": 4, "type": "paragraph", "text": "3.4"}
{"id": "051fc7bf-d9e9-4dfa-8eb2-44ae57278935", "page": 4, "type": "paragraph", "text": "44.6"}
{"id": "b7786fd1-2906-4ad4-9cea-fe08dead183f", "page": 4, "type": "paragraph", "text": "(18.8, 62.6)"}
{"id": "d06e1b58-8c4b-4a80-ba6a-097c4151da1e", "page": 4, "type": "paragraph", "text": "Sub-Type A"}
{"id": "ffc51210-02ab-43d3-8254-1e070fe8f486", "page": 4, "type": "paragraph", "text": "26"}
{"id": "5bcf7114-cacf-4ef9-9999-1338a5740198", "page": 4, "type": "paragraph", "text": "1.1"}
{"id": "3beb3eca-5d94-46a6-bcbc-92b8b386b0bf", "page": 4, "type": "paragraph", "text": "56"}
{"id": "cc5d1630-6419-4478-b676-bf57e3973495", "page": 4, "type": "paragraph", "text": "2.4"}
{"id": "7820b01f-3e3d-4f63-b7fb-b8db894ffc4f", "page": 4, "type": "paragraph", "text": "54.4"}
{"id": "930b86c2-32e7-461c-bfe2-0a34bc468f7a", "page": 4, "type": "paragraph", "text": "(26.1, 72.5)"}
{"id": "28315051-0525-429f-b8bd-ea307b44697a", "page": 4, "type": "paragraph", "text": "Type B"}
{"id": "231e43e4-4c4a-4484-b074-aefad4c1e2f0", "page": 4, "type": "paragraph", "text": "18"}
{"id": "6fee0237-a1a0-46cb-a5a4-77efbf7570c2", "page": 4, "type": "paragraph", "text": "0.8"}
{"id": "f31f1626-1e76-4db7-b74e-521a0a976ff3", "page": 4, "type": "paragraph", "text": "23"}
{"id": "e94ca967-580c-41ba-b27f-87c4bfea91d5", "page": 4, "type": "paragraph", "text": "1.0"}
{"id": "528b7bd9-8c24-4292-87df-0c710fe1346d", "page": 4, "type": "paragraph", "text": "23.1"}
{"id": "7ae06d4e-ee01-4004-82f6-93f5cfb6ceff", "page": 4, "type": "paragraph", "text": "(-49.0,"}
{"id": "9dc3eff8-e028-4424-86cd-8217294323d0", "page": 4, "type": "paragraph", "text": "60.9)"}
{"id": "5bb06640-f47d-47c7-9c62-2e290fc2418a", "page": 4, "type": "paragraph", "text": "Any ILI, all strains\u00b6"}
{"id": "955b8262-ebab-4691-b99c-cf876606555c", "page": 4, "type": "paragraph", "text": "64"}
{"id": "0c591443-3694-416e-bebf-1b7f06e8950b", "page": 4, "type": "paragraph", "text": "2.7"}
{"id": "b7eb32a0-2d29-4693-8577-105cea87b0b3", "page": 4, "type": "paragraph", "text": "114"}
{"id": "81848ebe-f483-49e9-b063-de53b908251f", "page": 4, "type": "paragraph", "text": "4.9"}
{"id": "f0c952d3-6b20-46e7-8879-618409399c8c", "page": 4, "type": "paragraph", "text": "44.8"}
{"id": "a6bc5c75-67cd-489b-9d86-3cf0362dafe5", "page": 4, "type": "paragraph", "text": "(24.4, 60.0)"}
{"id": "fd29f121-d170-4ead-9976-4e2c6a7a4032", "page": 4, "type": "paragraph", "text": "Sub-Type A"}
{"id": "15efd765-555b-4de8-b27a-2a5e75811b3e", "page": 4, "type": "paragraph", "text": "41"}
{"id": "956295bb-f9a1-4346-9cce-6cd83f2a9330", "page": 4, "type": "paragraph", "text": "1.7"}
{"id": "10fb87bc-3d59-439d-909a-e6b8c25fac1c", "page": 4, "type": "paragraph", "text": "79"}
{"id": "fa78ab4b-a76a-4514-a159-077765837f03", "page": 4, "type": "paragraph", "text": "3.4"}
{"id": "06738327-14d8-4e06-a26b-9e20fc380cbd", "page": 4, "type": "paragraph", "text": "49.0"}
{"id": "edf40f2a-440b-437a-bdc0-33b3cce666ca", "page": 4, "type": "paragraph", "text": "(24.7, 65.9)"}
{"id": "ee93326d-40ba-410f-b268-5ba09c6f196e", "page": 4, "type": "paragraph", "text": "Type B"}
{"id": "e01bd584-9c17-4ea3-ab64-e266b39abbf3", "page": 4, "type": "paragraph", "text": "23"}
{"id": "4d35a7de-1b27-4f1a-9cc5-09ff99543a8d", "page": 4, "type": "paragraph", "text": "1.0"}
{"id": "e8870c57-1bda-4f79-9234-6bcf6d71d873", "page": 4, "type": "paragraph", "text": "36"}
{"id": "320bc16f-12f0-4431-adce-9b00f457260b", "page": 4, "type": "paragraph", "text": "1.6"}
{"id": "61e1495f-c9e4-410f-a5eb-45ea7b6283ac", "page": 4, "type": "paragraph", "text": "37.2"}
{"id": "0eea67c0-c3ad-45ce-a851-2ec5a83d40d3", "page": 4, "type": "paragraph", "text": "(-8.9, 64.5)"}
{"id": "f7242749-e4e4-4560-b530-683afea79f41", "page": 4, "type": "paragraph", "text": "*In Study 1 (NCT00539981) vaccine efficacy analyses were conducted on the Total"}
{"id": "a1c31243-49e5-4ab8-a50e-3fb83143a60e", "page": 4, "type": "paragraph", "text": "Vaccinated Cohort (all randomized subjects who received study vaccine according to the"}
{"id": "ca0dc3c1-24f1-4a12-9aa3-d0fe2fc9a598", "page": 4, "type": "paragraph", "text": "treatment actually received and who provided data). Vaccine efficacy (VE) = 1 minus the"}
{"id": "cff06836-73e6-4c43-a90b-3f43d426fe1f", "page": 4, "type": "paragraph", "text": "ratio of Flublok/placebo infection rates."}
{"id": "0d408756-7827-46d5-9ebe-5f6b0f48028e", "page": 4, "type": "paragraph", "text": "\u2020Determined under the assumption of Poisson event rates, according to Breslow and Day,"}
{"id": "0cb9ca26-2873-48dd-932b-c5c5bdefe572", "page": 4, "type": "paragraph", "text": "1987."}
{"id": "c4f6fca6-215b-429f-a337-82c4cb87ca85", "page": 4, "type": "paragraph", "text": "\u2021Meets CDC in\ufb02uenza-like illness (CDC-ILI) de\ufb01ned as fever of \u2265100\u00b0F oral accompanied"}
{"id": "63e27e1c-198d-4789-8ca3-cee60c3af8ed", "page": 4, "type": "paragraph", "text": "by cough and/or sore throat, on the same day or on consecutive days."}
{"id": "bbc6a2f0-3e1a-43a7-979a-247193f80c6a", "page": 4, "type": "paragraph", "text": "\u00a7Primary endpoint of trial."}
{"id": "cc9247a5-64fc-43a2-80ee-a87f3216e6a9", "page": 4, "type": "paragraph", "text": "\u00b6All culture-con\ufb01rmed cases are considered, regardless of whether they quali\ufb01ed as"}
{"id": "4d87b51f-d862-489b-8e8e-ee85433fc606", "page": 4, "type": "paragraph", "text": "CDC-ILI."}
{"id": "90dae29e-8de8-4ef7-a006-fe72a60e9680", "page": 4, "type": "paragraph", "text": "#Secondary endpoint of trial."}
{"id": "270db19d-2148-42bd-be9b-2e64dcfaa8b9", "page": 4, "type": "paragraph", "text": "\u00deExploratory (prespeci\ufb01ed) endpoint of trial."}
{"id": "5459c01a-265d-443a-b13f-f78bbe555874", "page": 4, "type": "paragraph", "text": "The efficacy of Flublok Quadrivalent is relevant to Flublok because both vaccines are"}
{"id": "a018e18b-e0fc-44d1-a046-908969a89a07", "page": 4, "type": "paragraph", "text": "manufactured using the same process and have overlapping compositions (see Descrip-"}
{"id": "cfefdf0e-c62f-43aa-9608-b99fca79b933", "page": 4, "type": "paragraph", "text": "tion [11])."}
{"id": "fa650020-443d-4431-83f1-f5d3c572e4e1", "page": 4, "type": "paragraph", "text": "Study 6 evaluated the efficacy of Flublok Quadrivalent in a randomized, observer-blind,"}
{"id": "8ea27d84-0be4-4f0a-a5f5-afdaeb2eed4d", "page": 4, "type": "paragraph", "text": "active-controlled, multi-center trial conducted during the 2014-2015 in\ufb02uenza season in"}
{"id": "a932e3ed-11fe-486c-8614-a2ed94f14209", "page": 4, "type": "paragraph", "text": "adults 50 years of age and older. A total of 8963 healthy, medically stable adults (mean"}
{"id": "bb0d55c3-b1b3-4380-b15e-5b8d0c48ee55", "page": 4, "type": "paragraph", "text": "age 62.5 years) were randomized in a 1:1 ratio to receive a single dose of Flublok"}
{"id": "009ec94c-7007-4e54-b478-165efd12f0ea", "page": 4, "type": "paragraph", "text": "Quadrivalent (n=4474) or a U.S.-licensed quadrivalent inactivated in\ufb02uenza vaccine"}
{"id": "9e066547-b634-4ccf-8c9a-6ff64dfb08e9", "page": 4, "type": "paragraph", "text": "(Comparator, Fluarix Quadrivalent, manufactured by Glaxo SmithKline) (n=4489)."}
{"id": "edc462bc-c9ca-47ea-9d7a-69515454e941", "page": 4, "type": "paragraph", "text": "Among randomized subjects, 58% were female, 80% white, 18% black/African-American,"}
{"id": "15ebd331-5dff-471c-9cf8-f17d5baf2717", "page": 4, "type": "paragraph", "text": "2% other races, and 5% of Hispanic/Latino ethnicity. A total of 5186 (60%) subjects were"}
{"id": "882b9c2e-02df-4c46-a324-7204f760d2d9", "page": 4, "type": "paragraph", "text": "50-64 years of age and 3486 (40%) were \u226565 years of age. Real-time polymerase chain"}
{"id": "3ce01249-d2a4-49de-9d0e-3bbaf6944762", "page": 4, "type": "paragraph", "text": "reaction (rtPCR) -con\ufb01rmed in\ufb02uenza was assessed by active and passive surveillance for"}
{"id": "e5d41ecd-f0aa-47de-8e1e-2a09181e7181", "page": 4, "type": "paragraph", "text": "in\ufb02uenza-like illness (ILI) beginning 2 weeks post- vaccination until the end of the in\ufb02uenza"}
{"id": "578ad06b-bbec-4b89-a38f-bc9ad186726c", "page": 4, "type": "paragraph", "text": "season, approximately 6 months post- vaccination. ILI was de\ufb01ned as having at least one"}
{"id": "2500e616-1019-4869-8ed3-d752d3673c25", "page": 4, "type": "paragraph", "text": "symptom (no speci\ufb01ed duration) in each of two categories of respiratory and systemic"}
{"id": "a8390fad-85c6-4b60-856b-232297b63a0e", "page": 4, "type": "paragraph", "text": "symptoms. Respiratory symptoms included sore throat, cough, sputum production,"}
{"id": "17b28773-3768-4cf7-ad5f-709536de96f1", "page": 4, "type": "paragraph", "text": "wheezing and difficulty breathing. Systemic symptoms included fever > 99\u00b0F (>37\u00b0C) oral,"}
{"id": "09180666-59fc-4d4b-b155-bd09deceec38", "page": 4, "type": "paragraph", "text": "chills, fatigue, headache and myalgia. For subjects with an episode of ILI, a nasopha-"}
{"id": "d8c9fc12-802f-4ddc-b719-2777c49f4ad1", "page": 4, "type": "paragraph", "text": "ryngeal swab sample was collected for rtPCR testing and re\ufb02ex viral culture of rtPCR-"}
{"id": "f610e633-6f77-492c-923a-d85a9c8b4280", "page": 4, "type": "paragraph", "text": "positive samples."}
{"id": "7c4f38c2-d037-44c2-9b7d-e597e84ecfb3", "page": 4, "type": "paragraph", "text": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol-de\ufb01ned ILI due to"}
{"id": "20a0d04d-5d7b-4f2a-8ab7-7b93d08094d3", "page": 4, "type": "paragraph", "text": "any strain of in\ufb02uenza. Attack rates and relative vaccine efficacy (rVE), de\ufb01ned as 1 \u2013"}
{"id": "02c412b3-9646-462a-bb15-a66cf49277bf", "page": 4, "type": "paragraph", "text": "[Attack rate Flublok Quadrivalent/ Attack Rate Comparator], were calculated for the total"}
{"id": "2fabc475-aab8-4967-a998-6a23d65e2eca", "page": 4, "type": "paragraph", "text": "efficacy population (n=8604) for the primary efficacy endpoint and for several alternative"}
{"id": "40e151b2-ca21-420f-a670-9339a070a838", "page": 4, "type": "paragraph", "text": "efficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity"}
{"id": "427523b8-0a58-4a68-98dd-adc6ad1d674e", "page": 4, "type": "paragraph", "text": "(\u2033matching\u2033) of clinical isolates to vaccine antigens were not performed. CDC epidemio-"}
{"id": "b629882f-87f6-43c4-a7a9-58e005e7a8b5", "page": 4, "type": "paragraph", "text": "logical data for the 2014-2015 in\ufb02uenza season indicated that In\ufb02uenza A (H3N2) viruses"}
{"id": "9b2cddf8-9d72-4891-ac04-e07cdad4359f", "page": 4, "type": "paragraph", "text": "predominated and that most in\ufb02uenza A/H3N2 viruses were antigenically dissimilar while"}
{"id": "87632d9f-7b7d-41be-9b5c-0c122ca29cc3", "page": 4, "type": "paragraph", "text": "A/H1N1 and B viruses were antigenically similar to vaccine antigens."}
{"id": "c939c4e1-125e-4781-a583-9793c76e3a8d", "page": 4, "type": "paragraph", "text": "Table 5: Relative Vaccine Efficacy (rVE) of Flublok Quadrivalent versus"}
{"id": "5e353135-ab84-489d-a73e-914ac6a65b06", "page": 4, "type": "paragraph", "text": "Comparator against Laboratory-Con\ufb01rmed In\ufb02uenza, Regardless of Antigenic"}
{"id": "3f24551d-19da-49e8-b422-84ff5b90a689", "page": 4, "type": "paragraph", "text": "Similarity to Vaccine Antigens, Adults 50 Years of Age and Older, Study 6"}
{"id": "32c7dd57-7261-429f-b73b-867ede6cbe12", "page": 4, "type": "paragraph", "text": "(Efficacy Population)*,\u2020"}
{"id": "19bb2ac3-10fb-4745-b818-75afae302780", "page": 4, "type": "paragraph", "text": "Flublok"}
{"id": "6e6acea6-c144-4bab-832c-5ee4cfbeb718", "page": 4, "type": "paragraph", "text": "Quadrivalent"}
{"id": "d767b1d0-ba18-419b-a25a-ebbe1eac31bb", "page": 4, "type": "paragraph", "text": "(N=4303)"}
{"id": "7a956ad7-89e0-4d52-bfc5-f483751d453e", "page": 4, "type": "paragraph", "text": "Comparator"}
{"id": "bb1f3e51-b71c-4120-944c-7ee5b497035c", "page": 4, "type": "paragraph", "text": "(N=4301)"}
{"id": "f76e69ae-3dee-416c-82eb-ff45e82bacfc", "page": 4, "type": "paragraph", "text": "rVE %"}
{"id": "9bdef007-02af-48ec-9793-1ab707e85146", "page": 4, "type": "paragraph", "text": "(95% CI)"}
{"id": "2e05ad84-3de9-4104-a63d-81fa16af3c29", "page": 4, "type": "paragraph", "text": "n"}
{"id": "4b2503e2-ec93-4b40-b6c4-93a960ae5b16", "page": 4, "type": "paragraph", "text": "Attack"}
{"id": "92aadee2-5194-4351-859f-046842d2c5f9", "page": 4, "type": "paragraph", "text": "Rate"}
{"id": "f1ead8d6-19f6-4910-9af0-ad145365dcdf", "page": 4, "type": "paragraph", "text": "% (n/N)"}
{"id": "7cd24ae1-7250-49a2-9edc-4b9af73a60b4", "page": 4, "type": "paragraph", "text": "n"}
{"id": "b0566c42-19d8-4434-a732-3bdaeafbd2ed", "page": 4, "type": "paragraph", "text": "Attack"}
{"id": "3863bcbe-6803-44f4-bb08-0ad29827e07c", "page": 4, "type": "paragraph", "text": "Rate"}
{"id": "425f6cc0-8eea-4911-b13e-7c24569d5274", "page": 4, "type": "paragraph", "text": "% (n/N)"}
{"id": "7183fd8a-0718-4be4-ae52-62cb5c80de4f", "page": 4, "type": "paragraph", "text": "RR"}
{"id": "4f1fd81f-b966-4517-b12f-a215fc970f24", "page": 4, "type": "paragraph", "text": "All rtPCR-positive"}
{"id": "1d8c0962-1560-4b43-b3bd-cffd637974dd", "page": 4, "type": "paragraph", "text": "In\ufb02uenza\u2021"}
{"id": "cafe4f33-69b8-4462-8394-8273e2bfaa27", "page": 4, "type": "paragraph", "text": "96"}
{"id": "20a5ffe3-005c-4e98-aafb-88854f8cf161", "page": 4, "type": "paragraph", "text": "2.2"}
{"id": "ad9313f9-9de6-4625-9699-64741c1cd17b", "page": 4, "type": "paragraph", "text": "138"}
{"id": "b464324f-c471-4fc2-a89e-b9cdba588e31", "page": 4, "type": "paragraph", "text": "3.2"}
{"id": "949ed133-3bcf-42a8-aa06-17fb462417d5", "page": 4, "type": "paragraph", "text": "0.70"}
{"id": "370c91f5-eb7a-49c5-9923-0f3d48f90b18", "page": 4, "type": "paragraph", "text": "30 (10, 47)"}
{"id": "714a07ee-b9d2-4004-a777-28b913db7928", "page": 4, "type": "paragraph", "text": "All rtPCR-positive"}
{"id": "1248944c-c1f7-4299-97ac-cb3f287f1e2f", "page": 4, "type": "paragraph", "text": "In\ufb02uenza A\u00a7"}
{"id": "38e64836-5af5-47a4-8498-b98a29fdb082", "page": 4, "type": "paragraph", "text": "73"}
{"id": "fa28223d-86d1-4865-9901-d257cc5eb85c", "page": 4, "type": "paragraph", "text": "1.7"}
{"id": "22260a21-c49f-4759-a391-8450bcc24559", "page": 4, "type": "paragraph", "text": "114"}
{"id": "52310739-fc50-4307-a2e9-4e607a2fde09", "page": 4, "type": "paragraph", "text": "2.7"}
{"id": "a197cd62-b913-4884-9a4d-9bd154445e96", "page": 4, "type": "paragraph", "text": "0.64"}
{"id": "ec44679f-2200-400f-9894-5c141bad7b11", "page": 4, "type": "paragraph", "text": "36 (14, 53)"}
{"id": "69bc50ed-0836-43aa-9904-35923bf9daf5", "page": 4, "type": "paragraph", "text": "All rtPCR-positive"}
{"id": "c19944eb-2ff4-4496-8fe2-9a08baaef673", "page": 4, "type": "paragraph", "text": "In\ufb02uenza B\u00a7"}
{"id": "462bbcc8-31a6-4920-9655-0d493c0713f0", "page": 4, "type": "paragraph", "text": "23"}
{"id": "0b7a24d4-d948-4e63-aa33-6491bd3db297", "page": 4, "type": "paragraph", "text": "0.5"}
{"id": "45fd7f4e-f651-46fb-9d58-e5db0b02f50c", "page": 4, "type": "paragraph", "text": "24"}
{"id": "dbe1c9a7-57c7-4bc2-9c01-3a0d34229dee", "page": 4, "type": "paragraph", "text": "0.6"}
{"id": "2591093d-94c7-46c3-a828-563bb26ba815", "page": 4, "type": "paragraph", "text": "0.96"}
{"id": "e13e7e34-380e-4c50-a2ff-e002cbe5e95c", "page": 4, "type": "paragraph", "text": "4 (-72, 46)"}
{"id": "91e88251-7dbe-4e34-9cb3-d6d640d2464d", "page": 4, "type": "paragraph", "text": "All Culture-con\ufb01rmed"}
{"id": "4258b2b6-ccf8-48bb-a191-a6c30cfd1de8", "page": 4, "type": "paragraph", "text": "Protocol- de\ufb01ned ILI\u00a7,\u00b6"}
{"id": "510dc46c-beba-4972-a798-eabe287fbd0f", "page": 4, "type": "paragraph", "text": "58"}
{"id": "f3d7b0d3-2e22-4313-af9a-942d51bff5bc", "page": 4, "type": "paragraph", "text": "1.3"}
{"id": "4ffc56ce-8205-4f5e-af56-ebd848de341e", "page": 4, "type": "paragraph", "text": "101"}
{"id": "1296cf05-b687-4974-bdae-51cc17835cea", "page": 4, "type": "paragraph", "text": "2.3"}
{"id": "50480f67-e67f-49bb-bf00-4ae824f8fa6b", "page": 4, "type": "paragraph", "text": "0.57"}
{"id": "1d051d45-efa0-461c-aa05-68658ae4a97c", "page": 4, "type": "paragraph", "text": "43 (21, 59)"}
{"id": "11586933-376e-4d6f-bc82-05a3eb1b8fec", "page": 4, "type": "paragraph", "text": "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-"}
{"id": "a53a0595-f7c8-45e3-862e-fdbbc8c776f7", "page": 4, "type": "paragraph", "text": "licensed quadrivalent inactivated in\ufb02uenza vaccine, Fluarix Quadrivalent, manufactured by"}
{"id": "23ad3ba7-2170-4577-9fa6-aeb12f55118e", "page": 4, "type": "paragraph", "text": "GlaxoSmithKline; n=number of in\ufb02uenza cases; N=number of subjects in treatment group;"}
{"id": "2c176e0b-82b7-4ef8-9875-cb2d55429389", "page": 4, "type": "paragraph", "text": "RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]."}
{"id": "de68b725-5b45-4039-90bf-032a6570a9ad", "page": 4, "type": "paragraph", "text": "*Study 6 is registered as NCT02285998."}
{"id": "8fbdd394-5a02-4ed5-aea4-28f667236b65", "page": 4, "type": "paragraph", "text": "\u2020Efficacy Population included all randomized subjects who received study vaccine and"}
{"id": "67015f6c-4240-4d8e-b95f-2308f9345bf9", "page": 4, "type": "paragraph", "text": "provided any follow-up documentation for in\ufb02uenza-like illness beginning at least 14 days"}
{"id": "85b425b0-2e7f-4137-acbf-879452b59541", "page": 4, "type": "paragraph", "text": "post-vaccination. Excluded subjects with protocol deviations that could adversely affect"}
{"id": "daa909ae-d875-4668-9670-f61db2a12f08", "page": 4, "type": "paragraph", "text": "efficacy."}
{"id": "52fcbb2f-84a9-495f-b855-910f2ba5040a", "page": 4, "type": "paragraph", "text": "\u2021Primary Analysis. All cases of rtPCR-con\ufb01rmed in\ufb02uenza are included. Antigenic char-"}
{"id": "ec8f62f0-e384-4a67-ab65-b1420528834b", "page": 4, "type": "paragraph", "text": "acterization and genetic sequencing to determine similarity of isolates to vaccine antigens"}
{"id": "1c65b716-221b-4f49-b84c-d5bb5e0c71e1", "page": 4, "type": "paragraph", "text": "were not performed. CDC surveillance data indicated that the majority of in\ufb02uenza"}
{"id": "fa7001a4-2a34-4c92-91b2-0cd8f7f648b7", "page": 4, "type": "paragraph", "text": "A/H3N2 wild type viruses were antigenically distinct whereas in\ufb02uenza A/H1N1 and type"}
{"id": "48aee982-2fad-4899-af15-626af16bec3f", "page": 4, "type": "paragraph", "text": "B viruses were antigenically similar to vaccine antigens during the 2014-2015 season."}
{"id": "4b6c8a81-d586-4bf1-ad20-5e451f3acd2d", "page": 4, "type": "paragraph", "text": "Study 6 met the pre-speci\ufb01ed success criterion for the primary endpoint (lower limit of"}
{"id": "a863ef63-5ceb-4c1c-a6aa-85295e15b173", "page": 4, "type": "paragraph", "text": "the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator"}
{"id": "0546f825-11ae-44f6-ae59-debe31523f02", "page": 4, "type": "paragraph", "text": "should be not less than - 20%)."}
{"id": "097de690-98a2-4c1d-88f2-cefbdca9964d", "page": 4, "type": "paragraph", "text": "\u00a7Post hoc analyses. All cases of in\ufb02uenza A were A/H3N2. Cases of in\ufb02uenza B were not"}
{"id": "a2b708be-6320-4418-8e4c-577a4b081e08", "page": 4, "type": "paragraph", "text": "distinguished by lineage."}
{"id": "599ab52e-7a3a-4c56-83fc-275252574a50", "page": 4, "type": "paragraph", "text": "\u00b6Culture of rtPCR-positive samples was performed in MDCK cells."}
{"id": "9f48eb49-82d1-4f09-885a-05a206b07804", "page": 4, "type": "paragraph", "text": "15"}
{"id": "bda277b9-ab99-48f4-b090-dbf2ceb46fb4", "page": 4, "type": "paragraph", "text": "REFERENCES"}
{"id": "b82962cb-777f-47ed-9321-df524a317a8b", "page": 4, "type": "paragraph", "text": "1. Treanor JJ, El Sahly HM, King J, et. al. Protective efficacy of a trivalent recombinant"}
{"id": "94e4cf76-afef-4714-8253-3aa76d3ca790", "page": 4, "type": "paragraph", "text": "hemagglutinin protein vaccine (FluBlok) against in\ufb02uenza in healthy adults: a randomized,"}
{"id": "19dbed90-d333-4aa1-9c64-f2fa7c16e530", "page": 4, "type": "paragraph", "text": "placebo-controlled trial. Vaccine. 2011, Vol. 29, pp. 7733-7739."}
{"id": "47d2097b-f87f-48f1-81ba-3c12a09315b8", "page": 4, "type": "paragraph", "text": "2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and"}
{"id": "2d2c00f0-6198-4042-8fc1-586f2a126ee7", "page": 4, "type": "paragraph", "text": "immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin"}
{"id": "845f8119-a7c9-454b-b36d-7ea42953d971", "page": 4, "type": "paragraph", "text": "in\ufb02uenza vaccine administered intramuscularly to healthy adults 50-64 years of age."}
{"id": "1fd189ff-80f7-4aad-8317-17ecc9949dfd", "page": 4, "type": "paragraph", "text": "Vaccine. 2011, Vol. 29, pp. 2272-2278."}
{"id": "26b9e325-caf5-4456-b212-a89b8dfa867e", "page": 4, "type": "paragraph", "text": "3. Keitel WA, Treanor JJ, El Sahly HM, et.al. Comparative immunogenicity of recom-"}
{"id": "4d5460af-d3b4-403f-a04c-dad20253cc8d", "page": 4, "type": "paragraph", "text": "binant in\ufb02uenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among"}
{"id": "fc82f636-50ba-4855-af8e-f6b6ed1eae9e", "page": 4, "type": "paragraph", "text": "persons \u226565 years old. Vaccine. 2009, Vol. 28, pp. 379-385."}
{"id": "bb85acd6-1e29-4735-b347-a924a4fe55de", "page": 4, "type": "paragraph", "text": "4. Izikson R, Leffell DJ, Bock SA, et. al. Randomized comparison of the safety of"}
{"id": "def72653-12c4-486c-be9a-1c0bc9e92037", "page": 4, "type": "paragraph", "text": "Flublok\u00aeversus licensed inactivated in\ufb02uenza vaccine in healthy, medically stable adults"}
{"id": "226c1e83-b2d2-4772-8eb5-776f1f06d2e0", "page": 4, "type": "paragraph", "text": "\u226550years of age. Vaccine. 2015, Vol. 33, pp. 6622\u20136628."}
{"id": "7236f260-6b65-4fd8-aa32-9d9419b42b7e", "page": 4, "type": "paragraph", "text": "5. Treanor JJ, Schiff GM, Hayden FG, et.al. Safety and immunogenicity of a baculovirus-"}
{"id": "52653203-53c9-43be-a62c-6cc49b7fe911", "page": 4, "type": "paragraph", "text": "expressed hemagglutinin in\ufb02uenza vaccine: a randomized controlled trial. JAMA. 2007,"}
{"id": "9b8f463d-d952-4e01-ac46-5d029e778d6e", "page": 4, "type": "paragraph", "text": "Vol. 297, pp. 1577-1582."}
{"id": "6a3039e7-0d7a-4a53-99a7-eee2cffebc5a", "page": 4, "type": "paragraph", "text": "6. King JC, Cox MMJ, Reisinger K, et. al. Evaluation of the safety, reactogenicity and"}
{"id": "9384c53b-7982-4b6f-8142-37a3fb233f63", "page": 4, "type": "paragraph", "text": "immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin"}
{"id": "29e251bf-3fb3-4629-9917-e1f3059746e6", "page": 4, "type": "paragraph", "text": "in\ufb02uenza vaccine administered intramuscularly to healthy children aged 6-59 months."}
{"id": "6f062314-70d4-411d-9c78-1da8d245beec", "page": 4, "type": "paragraph", "text": "Vaccine. 2009, Vol. 27, pp. 6589-6594."}
{"id": "614b092d-5717-4d07-8cc3-42318d72e650", "page": 4, "type": "paragraph", "text": "7. CBER/FDA. Guidance for Industry: Clinical Data Needed to Support the Licensure of"}
{"id": "1254d010-8a7f-4dec-bf2a-e5b5706e91fe", "page": 4, "type": "paragraph", "text": "Seasonal Inactivated In\ufb02uenza Vaccines. s.l. : DHHS/CBER/FDA, 2007."}
{"id": "93c72956-a54b-49e4-b4bd-581fba1b90a9", "page": 4, "type": "paragraph", "text": "16"}
{"id": "f3ac0ae5-d127-4376-8768-9fd41a598fe5", "page": 4, "type": "paragraph", "text": "HOW SUPPLIED/STORAGE AND HANDLING"}
{"id": "5bcc4a9a-f623-460d-bd77-ea5ea9a9c148", "page": 4, "type": "paragraph", "text": "16.1 How Supplied"}
{"id": "a9e068cb-05a0-48d9-9770-fcbdc837f936", "page": 4, "type": "paragraph", "text": "Flublok is supplied as a single-dose, 0.5 mL pre\ufb01lled syringe in a 10 syringe carton."}
{"id": "1702ce5c-8044-4e08-8fdb-fb382cdce29d", "page": 4, "type": "paragraph", "text": "Presentation"}
{"id": "cc86b4ad-6a85-4f24-bb4d-efc40b88f4e7", "page": 4, "type": "paragraph", "text": "Carton NDC"}
{"id": "ed034258-2a0a-4da6-b09c-5d3040a14306", "page": 4, "type": "paragraph", "text": "Number"}
{"id": "f17dd479-34cc-46a7-8cae-e7f88dc569e1", "page": 4, "type": "paragraph", "text": "Components and NDC Number"}
{"id": "d1cc37b0-962e-4502-9ccb-89da39abf51f", "page": 4, "type": "paragraph", "text": "Single-Dose"}
{"id": "e06a142b-26ae-4d91-bd45-d77981c3584e", "page": 4, "type": "paragraph", "text": "Pre\ufb01lled Syringe"}
{"id": "7a19641d-a80d-4010-9ab3-6cf5f3847d00", "page": 4, "type": "paragraph", "text": "49281-724-10"}
{"id": "de9361bf-0ada-4545-95f7-5ecef5ca329b", "page": 4, "type": "paragraph", "text": "Ten 0.5 mL single-dose pre\ufb01lled"}
{"id": "3097b777-8e87-4351-a298-5e6a6a4a26ee", "page": 4, "type": "paragraph", "text": "syringes [49281-724-88]"}
{"id": "7bd136aa-e495-4ee0-a8f8-cd9e5d9d80f7", "page": 4, "type": "paragraph", "text": "16.2 Storage and Handling"}
{"id": "82e90a9b-d439-4f68-962f-55e5bfe65dd7", "page": 4, "type": "paragraph", "text": "\u2022 Store refrigerated between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F)."}
{"id": "22cad161-fcde-4060-8803-78b103c66f6c", "page": 4, "type": "paragraph", "text": "\u2022 Do not freeze. Discard if product has been frozen."}
{"id": "e6bb6154-e9aa-4975-88c6-54079622340e", "page": 4, "type": "paragraph", "text": "\u2022 Protect syringes from light."}
{"id": "7e204fc1-f34c-4fbd-b9ce-ad6a6022fb7b", "page": 4, "type": "paragraph", "text": "\u2022 Do not use after expiration date shown on the label."}
{"id": "1e662721-e1bc-49cd-bd00-88809b49eef3", "page": 4, "type": "paragraph", "text": "17"}
{"id": "ec9f12ce-0917-46d0-b61c-f1d79e9adf78", "page": 4, "type": "paragraph", "text": "PATIENT COUNSELING INFORMATION"}
{"id": "9ce8f870-9eb4-435c-a9ab-0500158a48cc", "page": 4, "type": "paragraph", "text": "Inform the vaccine recipient of the potential bene\ufb01ts and risks of vaccination with Flublok."}
{"id": "0f35d14d-4e19-4e56-ae48-b5fffe62b906", "page": 4, "type": "paragraph", "text": "Inform the vaccine recipient that:"}
{"id": "0da48101-4f09-4f9f-bdc2-c8d5edf8a5b5", "page": 4, "type": "paragraph", "text": "4"}
{"id": "310040b4-2c0f-46d4-870d-3773e0efd6e1", "page": 5, "type": "paragraph", "text": "\u2022 Flublok contains non-infectious proteins that cannot cause in\ufb02uenza."}
{"id": "c784adc4-20b3-44d5-86f5-1310fedcb8da", "page": 5, "type": "paragraph", "text": "\u2022 Flublok stimulates the immune system to produce antibodies that help protect against"}
{"id": "af59b73d-0cb7-4aae-9094-d9cbeb26da76", "page": 5, "type": "paragraph", "text": "in\ufb02uenza viruses contained in the vaccine but does not prevent other respiratory"}
{"id": "d172d754-0870-42ce-b630-d43a3a04056b", "page": 5, "type": "paragraph", "text": "infections."}
{"id": "b436383f-1a44-4a9a-9466-a5c89f3b2aef", "page": 5, "type": "paragraph", "text": "Instruct the vaccine recipient to report any adverse events to their healthcare provider"}
{"id": "22c33b92-d670-4f94-ac21-ca1942d95376", "page": 5, "type": "paragraph", "text": "and/or to the Vaccine Adverse Event Reporting System (VAERS)."}
{"id": "08940186-6446-4b58-8b95-8bc6756f4090", "page": 5, "type": "paragraph", "text": "Provide the vaccine recipient with the Vaccine Information Statements which are required"}
{"id": "722de490-ed1e-461b-9e83-659f4c26bea3", "page": 5, "type": "paragraph", "text": "by the National Childhood Vaccine Injury Act of 1986 to be given prior to vaccination."}
{"id": "55c60a6f-3e6d-425c-827a-1acb6b8585fd", "page": 5, "type": "paragraph", "text": "These materials are available free of charge at the Centers for Disease Control (CDC)"}
{"id": "3358b77f-5ac9-4cae-8200-bf01de38f722", "page": 5, "type": "paragraph", "text": "website (www.cdc.gov/vaccines)."}
{"id": "5d3e1cc9-d6d3-498a-a754-7c358d24794f", "page": 5, "type": "paragraph", "text": "Encourage women who receive Flublok while pregnant to notify Sano\ufb01Pasteur Inc."}
{"id": "5d90aa4a-a799-456b-b32d-ef9de61865ee", "page": 5, "type": "paragraph", "text": "sano\ufb01pasteurpregnancyregistry.com or by calling 1-800-822-2463 (1-800-VACCINE)."}
{"id": "0cea12a8-7bb6-46f8-9f23-f2cfdcb2d5cc", "page": 5, "type": "paragraph", "text": "Instruct the vaccine recipient that annual vaccination to prevent in\ufb02uenza is recommended."}
{"id": "05bdb2b9-111d-4e0a-9dda-2ea3c5d10d1a", "page": 5, "type": "paragraph", "text": "Manufactured by Protein Sciences Corporation (Meriden, CT) U.S. license No. 1795."}
{"id": "fbaba04b-7d8f-402a-8be3-1053c993247e", "page": 5, "type": "paragraph", "text": "Distributed by Sano\ufb01Pasteur Inc."}
{"id": "dcc5f206-03cf-4d86-bf9d-e6cf2d86f755", "page": 5, "type": "paragraph", "text": "Flublok is a registered trademark of Protein Sciences Corporation."}
{"id": "31dfa34f-01bf-4d28-b6f4-68af55e7b997", "page": 5, "type": "paragraph", "text": "INFB4-FPLR-SL-JUL24"}
{"id": "36022c8e-90f2-4678-a5a2-723b3f062f1b", "page": 5, "type": "paragraph", "text": "Rx Only"}
{"id": "bc9c4ae2-87c7-4d3d-9e40-f35cabd53bf4", "page": 5, "type": "paragraph", "text": "5"}
